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ABSTRACT 
 
The increasing occurrence of Fusarium fungi and associated mycotoxins in cereal grains 
is a significant issue for global agriculture. The mycotoxin deoxynivalenol (DON) is the most 
prevalent feed contaminant worldwide and causes a variety of adverse effects in animals. While 
the individual toxicity of DON is a concern, exposure to multiple mycotoxins in feed is more 
common, necessitating information on the outcome of mixture exposures. However, 
characterizing the toxicity of DON and other mycotoxins has been difficult due to highly varied 
responses in long-term animal feeding trials. In addition, resources required for whole animal 
testing are only amplified in combinatorial mycotoxin studies given the large sample sizes and 
number of treatment groups required. The chicken embryo has been widely and successfully 
utilized as a non-animal alternative to evaluate the toxicity of environmental pollutants and could 
be used as a screening tool to evaluate mycotoxin mechanisms of action and mixture toxicity. 
The overall objective of this thesis research is to characterize the effects of DON (administered 
in ovo) alone and in combination with a commonly co-occurring mycotoxins, zearalenone 
(ZEA), to the late-term chicken embryo in order to determine whether an in ovo approach for 
conducting exposures to Fusarium mycotoxins could be used as a predictive tool for assessing 
the toxicity of Fusarium mycotoxins alone and in combination. The overall hypothesis is that 
responses of the late-term chicken embryo to single doses of Fusarium mycotoxins, alone or in 
combination, are similar to those reported in whole animal feeding trials with poultry.  
In the first experiment, the effect of in ovo administration of DON was evaluated in terms 
of embryotoxicity, growth and development, pathological changes to tissue, and 
biochemical/molecular indicators of oxidative and immune stress. A single injection of purified 
DON was administered to the late-term chicken embryo (embryonic day 14, ED14) at five doses 
ranging from 0.0 – 5.0 μg DON/g egg weight. Eggs were opened on ED20 and embryos were 
evaluated for survivability and growth parameters. Tissues were sampled for subsequent 
analysis. At the highest dose, DON decreased embryo survivability and increased the absolute 
and relative weight of both liver and spleen. Hepatic bile stagnation and concurrent splenic 
inflammation were frequently detected among groups receiving 5.0 and 1.0 μg DON/g egg 
weight but were observed less often in the latter. A dose-dependent increase in granulopoiesis 
and lipid peroxidation (as measured by TBARS assay) were observed in the liver; however, 
mRNA expression of genes related to immune and oxidative stress were mostly unchanged. 
These results suggest that the chicken embryo responds to in ovo DON exposure with effects on 
 iii 
immunity and oxidative stress that are supported by previous in vivo and in vitro findings. The in 
ovo approach developed and validated in the first experiment was then carried forward to a 
second experiment with the aim of characterizing the combined toxicity of DON and another 
mycotoxin, ZEA to the chicken embryo. ZEA was chosen for this experiment because the 
combination of DON and ZEA is considered to be the most prevalent mycotoxin mixture in 
North America and worldwide. Treatments included an untreated control group (CON), a 
vehicle-injected control group (20% DMSO), 0.5 and 2.5 μg DON/g egg weight, 0.5 and 2.5 μg 
ZEA/g egg weight, and a low and high combination treatment at 0.5 μg DON + 0.5 μg ZEA/g 
egg weight and 2.5 μg DON + 2.5 μg ZEA/g egg weight, respectively. The results demonstrated 
that interactive effects of DON and ZEA differed across endpoints and tended to vary from 
antagonistic at low doses to non-interactive or possibly potentiated at high doses. At low doses, 
DON and ZEA had antagonistic effects on liver weight as well as liver lipid peroxidation. At 
high doses, effects of DON and ZEA were mostly independent and effects of DON, specifically, 
were in line with our previous observations. At a combined, high dose of DON and ZEA there 
was evidence of possible potentiation with respect to embryo survivability, hepatic bile 
stagnation and splenic inflammation, and hepatic granulopoiesis. These results suggest the 
chicken in ovo model is useful for studying combinatorial mycotoxin toxicity; however, further 
research regarding ZEA-induced toxicity would improve response interpretation. Overall, the 
results presented in this thesis indicate that in ovo responses to Fusarium mycotoxins, alone and 
in combination, are supported by previous in vitro and in vivo findings. While in ovo mycotoxin 
exposures cannot replace in vivo experimentation, there is potential for the in ovo model to 
inform whole animal studies by identifying and prioritizing emerging mycotoxins and high-risk 
mycotoxin combinations for further in vivo assessment. In the future, the in ovo model could be 
used in a more practical application as a rapid-screening tool to assess the toxicity of mycotoxin 
grain extracts or to evaluate the efficacy of new mycotoxin mitigation techniques. 
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NOTE TO READER 
 This thesis is organized and formatted to follow the University of Saskatchewan College 
of Graduate and Postdoctoral Studies guidelines for a manuscript-style thesis. Therefore, there is 
some repetition between the material presented in each chapter. Chapter 1 of this thesis is a 
review of the current literature as it pertains to mycotoxin occurrence, individual and combined 
toxicity of mycotoxins with special reference to poultry, the applicability of in ovo exposures for 
evaluating mycotoxin toxicity and concludes with research hypothesis and objectives. Chapter 4 
is a general discussion containing major conclusions of the thesis research. Chapter 2 and 
Chapter 3 are organized as manuscripts for publication in peer-reviewed scientific journals and a 
description of author contributions is provided following the preface for these chapters. 
References cited in each chapter are combined and listed in the References section of the thesis.
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CHAPTER 1 
 
LITERATURE REVIEW 
  
 2 
1.1 Fusarium fungi and associated mycotoxins in Canada 
The infection of cereal grains by Fusarium fungi is an increasingly prevalent issue for 
global agriculture. Fusarium fungal diseases compromise the quality and yield of crops while 
accumulation of toxic fungal metabolites, known as mycotoxins, within the grains themselves 
makes them unsafe for human and animal consumption. The two main diseases generated by 
Fusarium infection in cereals are Fusarium Head Blight (FHB) and Fusarium Crown Rot (FCR), 
both of which are observed in cereal crops like wheat, barley, rye, oats and triticale (Fouroud et 
al., 2014). The major species responsible for FCR is Fusarium pseudograminearnum and 
although occasionally found in Canada, this species tends to prefer warmer climates (Miller and 
Richardson, 2013). More relevant to Canadian production is the disease FHB and its causative 
agents, Fusarium graminearum and Fusarium culmorum. These species are known to be highly 
pathogenic and abundant and under stressful conditions (i.e. nutritional imbalance, drought, 
water excess etc.), can produce mycotoxins that accumulate in grains (Rodrigues and Naehrer, 
2012) – primarily deoxynivalenol (DON; Figure 1.1: A) and zearalenone (ZEA; Figure 1.1: B) in 
cooler climates (Schatzmayr and Streit, 2013). These mycotoxins are likely the most relevant to 
Canadian production and confer the most risk to human and animal health. Although not as 
acutely toxic as some mycotoxins, DON is the most common and abundant mycotoxin in Canada 
and throughout the world (Rodrigues and Naehrer, 2012). Tittlemier et al. (2013) quantified 
DON in 75% of Canadian western amber durum samples obtained in the 2010 Canadian Grains 
Commission Harvest Sample Program. A recent global mycotoxin survey reported that, in North 
America, DON and ZEA contaminated 83% and 42% of finished feed samples, respectively 
(Biomin, 2017). Similar to DON, ZEA is not considered acutely toxic but behaves estrogenically 
and thus, is biologically potent.  
 
    
 
 
 
 
 
Figure 1.1 The chemical structure of the Fusarium mycotoxins deoxynivalenol (DON; A) and 
zearalenone (ZEA; B) (Sigma–Aldrich Corporation, St. Louis, MO, USA). 
A B 
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Mycotoxin concentration is a significant factor in the grading of wheat and durum and 
with 75% of Canadian wheat exported, mycotoxin contamination confers significant economic 
losses to the agricultural sector (Tittlemier et al., 2013). Within the United States, estimated total 
economic loss due to mycotoxin contamination average $932 million per year (CAST report, 
2003). The Food and Agricultural Organization (FAO) estimates 25% of the world’s crops are 
affected by mycotoxins and that food and food product losses near 1 billion metric tons (2007). 
Crop losses due to mycotoxin contamination will increase globally in the future as incidence of 
mycotoxins in grain crops continues to rise.  
In Canada, conditions favoring the development of Fusarium infection have been, in part, 
attributed to increasing mycotoxin levels. It is well known that temperature and precipitation 
around the time of flowering (anthesis) are important factors in Fusarium infection of cereals, 
such as wheat (Bailey et al., 2003), and high levels of mycotoxin contamination are linked to 
unusual weather (Schatzmayr and Streit, 2013). While the climate of western Canada has 
historically been effective at hindering Fusarium species, increasing yearly moisture during 
anthesis has promoted fungal spread and thus, the production of mycotoxins. Moreover, the 
genetics of Fusarium species on the prairies is shifting and, in turn, altering mycotoxin matrices 
in grains. The fusario-mycotoxin DON is produced by Fusarium via two precursor pathways: 15-
acetyl DON (15-ADON) and 3-acetyl DON (3-ADON). Isolates from the 3-ADON chemotype 
have been shown to produce significantly more DON per kernel and have increased growth rates 
as compared to 15-ADON (Ward et al., 2008). Historically, the 15-ADON chemotype has 
dominated in western Canada; however, data shows that the 3-ADON chemotype is becoming 
increasing prevalent (Canadian Grains Commission, 2008). This shift ultimately results in a 
higher overall concentration of DON within Fusarium infected grains. 
 
1.1.1 Regulating mycotoxins in livestock feed 
Currently, many regulatory bodies (i.e. Canadian Food Inspection Agency, CFIA; Food 
and Drug Administration, FDA; European Union; EU) impose limits on the concentration of 
mycotoxins permitted in animal feed. Various factors contribute to the establishment of 
mycotoxin limits including scientific, economic, or political factors (van Egmond, 2002); thus, 
maximum inclusion levels vary across countries. In Canada, only a small proportion of all 
mycotoxins are subject to limitation and these include aflatoxins (AFs), ochratoxin (OTA), 
fumonisins (FUM), diacetoxyscirpenol, ergot, T-2 toxin, HT-2 toxin as well as DON and ZEA 
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(CFIA, 2015). Compliance with limits is ensured by regular testing of grains along the grain 
handling and processing chain (Foroud et al., 2014) – domestic and export grain shipments are 
monitored by the Canadian Grains Commission (CGC) while designated feed commodities are 
monitored by the CFIA. However, it is important to note that only levels of aflatoxin in feed are 
actually regulated while all other existing limits are recommended guidelines (CFIA, 2015). 
Whether recommended or legislated, maximum levels for mycotoxins are designed to prevent in-
feed mycotoxin concentrations that cause mycotoxicosis or reduced growth performance in 
livestock, and/or to prevent carry-over of mycotoxins to animal products designated for human 
consumption. Regulatory bodies such as the CFIA defines those maximums based on the 
sensitivity of species to individual mycotoxins. What current limits in Canada, and worldwide, 
do not consider is that feed commodities are often co-contaminated by mycotoxins (Smith et al., 
2016) and interactions between mycotoxins in the feed matrix are likely to increase their toxic 
effect (Grenier and Oswald, 2011). This limitation can mainly be attributed to the lack of 
information regarding interactive toxicity of mycotoxins (Smith et al., 2016). While it would be 
nearly impossible to characterize the toxicity of every mycotoxin combination for each livestock 
species, identification and characterization of particularly high-risk combinations would provide 
relevant information to the livestock industry.  
 
1.1.2  Co-occurrence of mycotoxins 
Co-occurrence of mycotoxins can be explained by the fact that 1) most Fusarium fungi 
produce several mycotoxins concurrently, 2) several fungi can contaminate feed commodities 
simultaneously or in quick succession, and 3) animal diets are usually made up of multiple grain 
sources (Smith et al., 2016). A recent, world-wide survey of feeds and raw feed ingredients 
identified more than one mycotoxin in 71% of 18,757 samples tested (Biomin, 2017). In North 
America, specifically, a similar survey reported that 48% of raw feed ingredients and 40% of 
finished feeds in North America contained two or more mycotoxins (Rodrigues and Naehrer, 
2012). The most commonly detected co-occurring mycotoxins include Fusarium toxins (namely 
type B-trichothecenes (like DON), ZEA, and FUM), AFs and OTA, in various combinations 
(Streit et al., 2012). Indeed, in their meta-analyses, Smith et al. (2016) identified binary 
combinations of AFs+FUM, AFs+OTA, FUM+ZEA and DON+ZEA as the most frequently 
observed in cereals and cereal product samples. This analyses also concluded that the 
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combination of DON + ZEA was the most prevalent mycotoxin combination in North America 
(Smith et al. 2016).  
As discussed above, current regulations do not reflect the combinatorial nature of 
mycotoxins, despite the frequency of mycotoxin co-contamination in feed, as data on combined 
toxicity of mycotoxins are varied and limited (Smith et al., 2016). Generally, we can see that 
naturally contaminated feed has a more potent effect in terms of toxicity when compared to feed 
that is spiked with a single pure mycotoxin (reviewed in Eriksen and Petterson, 2004). This 
discrepancy is often attributed to the presence of masked, previously undescribed or co-occurring 
mycotoxins, that have not been tested for, acting in sync with known mycotoxins (Schatzmayr 
and Streit, 2013; Dersjant-Li et al., 2003; Trenholm et al., 1994). Similarly, co-occurring 
mycotoxins can interact in various ways and these interactions can be defined as additive, 
synergistic, permissive (or potentiated), or antagonistic. Regarding effects on animal 
performance, most studies report additive or synergistic interactions of co-occurring mycotoxins 
(Grenier and Oswald, 2011). This means that co-contaminated samples with individual 
concentrations even below those recommended by regulatory bodies may still exert effects due 
to synergistic interactions of the mycotoxins (Schatzmayr and Streit, 2013), explaining in part 
why animals sometimes react adversely to feed, despite compliant mycotoxin levels (Rodrigues 
and Naehrer, 2012).  
Evaluating the adverse effects of mycotoxin mixtures provides more relevant information 
to the livestock industry; however, as previously mentioned, there is limited information 
available in this context, particularly in the whole animal. Several authors have identified the 
need for combinatorial mycotoxin research to support improved in-feed guidelines (Speijers and 
Speijers, 2004; Grenier and Oswald, 2011; Streit et al., 2012; Smith et al., 2016). While many 
studies exist on the individual toxicity of mycotoxins, in practice, the outcome of combined 
exposure may be qualitatively or quantitatively different from what would be predicted based on 
individual toxicity (Speijers and Speijers, 2004).  
 
1.2 Mechanisms of Action 
1.2.1 Deoxynivalenol (DON) 
Toxicity of DON is conferred primarily through potent inhibition of protein synthesis and 
induction of apoptosis (Rotter et al., 1996). Maresca et al. (2002) showed that effects of DON 
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were mimicked by protein synthesis inhibitors and apoptosis inducers and suggested that 
inhibition of protein synthesis and induction of apoptosis are the main mechanisms of DON 
toxicity. These actions are accomplished by the interaction of DON with cellular targets. Within 
the cell, DON binds the 60S ribosomal subunit and exerts translational inhibition (Ueno, 1984), 
while also rapidly activating mitogen-activated protein kinases (MAPKs) including p38, c-Jun 
N-terminal kinase (JNK) and extracellular-signal regulated kinase (ERK) (Shifrin and Anderson, 
1999). Cascades initiated by MAPK activation are essential in regulating cellular processes such 
as proliferation, differentiation, stress responses, and apoptosis (Cobb, 1999). Specifically, DON-
mediated activation of MAPKs is known to initiate a ribotoxic stress response that ultimately 
leads to induction of apoptosis (reviewed in Pestka, 2008). Rapid regeneration of cells is 
essential for highly-proliferating tissues such as the liver, gut, and immune tissues and cells; 
however, the adverse effect of DON alters the generation of cells which can impede overall 
tissue function (Bondy and Pestka, 2000; Döll et al., 2003; Bony et al., 2006; Pinton and Oswald, 
2014). Moreover, MAPK cascades also play a critical role in signal transduction in immune 
responses (Dong et al., 2002). When MAPK cascades are activated, transcription factors are 
altered to increase the expression of pro-inflammatory cytokines. In addition to apoptosis and 
protein synthesis inhibition, DON causes MAPK-mediated upregulation of both cytokines and 
chemokines that favour inflammatory pathways (Zhou et al., 2003). In practice, exogenous 
activation of MAPKs by DON translates into anorexia, reduced weight gain, altered nutritional 
efficiency, tissue injury and immunomodulation when exposure is prolonged (reviewed in 
Pestka, 2007).  
 
1.2.2 Zearalenone (ZEA) 
Although classified as non-steroidal estrogen, ZEA is structurally similar to 17β-estradiol 
and thus the adverse effects of ZEA are primarily attributed to its ability to mimic and compete 
with endogenous estrogens (Metzler et al., 2010). In terms of estrogenic capacity, ZEA enters the 
cytoplasm of cells via passive diffusion where it binds dormant, nuclear estrogen receptors and 
subsequently initiates shedding of heat shock proteins, acquisition of co-activators, and the 
formation of homo- and heterodimers. Activated dimers then bind estrogen response elements 
(ERE) in regulatory areas of DNA responsible for estrogen-responsive messenger RNA (mRNA) 
synthesis and subsequent production of gene products. Beyond genomic mechanisms, there is 
evidence that ZEA exerts estrogenic effects by binding both cytoplasmic estrogen receptors 
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(Tiemann et al., 2003) and membrane receptors (G-protein coupled receptors; He et al., 2018). 
Importantly, ZEA and its metabolites do not have equal affinity for estrogen receptors. 
Generally, ZEA is metabolized by dehydrogenases to either α-or β-zearalenol (ZEL). The 
affinity of β-ZEL for the estrogen receptor is approximately 2.5 times lower than ZEA while the 
affinity of α-ZEL is approximately 92 times higher (Fitzpatrick et al., 1989). The 
biotransformation to β-ZEL is therefore regarded as an inactivation pathway, whereas the 
biotransformation to α-ZEL is seen as bioactivation (Malejinekad et al., 2006). 
 
1.3 Toxic effects of DON and ZEA with special reference to poultry 
The recommended limit for DON inclusion in poultry diets is among the highest for 
production animals at 5 mg/kg (parts per million, ppm), while limits for other monogastrics, such 
as humans and swine, are restricted to 1 mg/kg (CFIA, 2015; European Commission 2006; FDA 
2012). Poultry are widely considered to be resistant to DON, mainly owing to rapid clearance of 
DON and low bioavailability (<1%) at the tissue level (Prelusky et al., 1986). Moreover, large 
intestine fluids (colon and ceca) from laying hens have demonstrated the capacity to detoxify 
DON (Lun et al. 1988; He et al. 1992). Despite the observed tolerance of poultry to DON, there is 
evidence that poultry species respond adversely to feed at inclusion levels below 5 mg/kg (Awad 
et al., 2006; Awad et al., 2011; Awad et al., 2013; Antonissen et al., 2014).  
There is limited data on the toxicity of ZEA to poultry reported to date. Early studies 
found that dietary exposure to ZEA up to 800 mg/kg had no effect on the performance, 
morphology, fertility, reproductive histology or hematology of poultry (Chi et al., 1980; Allen et 
al., 1981). Less information is available regarding the toxicokinetics of ZEA in poultry but 
according to Malejinekad et al. (2006), the less-estrogenic metabolite of ZEA, b-ZEL, is the 
primary product of ZEA metabolism in the chicken liver and poultry are regarded as ZEA-
resistant. While regulatory guidelines exist for in-feed DON inclusion, major governing bodies do 
not currently impose dietary limits for ZEA in poultry feed (CFIA, 2015; European Commission 
2006; FDA 2012) meaning that high levels of ZEA can occur in poultry diets alongside DON.  
 
1.3.1 Oxidative stress 
Oxidative stress arises when the concentration of reactive oxygen species (ROS) exceeds 
the antioxidant capacity of cells/tissues (Sies, 1991). Excess ROS then are able to elicit cell 
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damage by directly targeting critical macromolecules such as DNA, proteins, and lipids. If 
enough cell damage is incurred, ROS-dependent cell death can be stimulated through either 
necrotic or apoptotic pathways. Recently, oxidative stress pathways have been highlighted as an 
additional mechanism of DON toxicity with in vitro exposures to DON demonstrating DON-
dependent ROS generation (reviewed in Mishra et al., 2014). Increased concentrations of ROS 
were found in immune (chicken splenic lymphocytes and isolated broiler lymphocytes) and non-
immune (chicken embryo fibroblasts) cells following in vitro exposure to DON (Ren et al., 2015; 
Lautert et al., 2014; Li et al., 2014; respectively). An early study in mice reported that dietary 
exposure to DON increased hepatic lipid peroxides by 21% (Rizzo et al., 1994). In the studies of 
Lautert et al. (2014) and Li et al. (2014), exposure to DON and subsequent accumulation of ROS 
was accompanied by increase malondialdehyde (MDA) levels – the primary product of lipid 
peroxidation. This is supported by in vivo evidence that demonstrated a similar elevation of 
MDA in the jejunum (Awad et al., 2014), liver, and kidney (Borutova et al., 2008) of broiler 
chickens receiving DON-contaminated diets. Lipid peroxidation initiated by ROS causes damage 
to phospholipids and lipoproteins of the cell membrane and is a primary mechanism for ROS-
mediated oxidative damage (Braca et al., 2002). Protection from ROS is mainly accomplished by 
the antioxidant enzyme glutathione (GSH) and its co-substrate glutathione peroxidase (GPx). 
Reduction in GSH (Li et al., 2014) and activity of GPx (Dragomir et al., 2007; Costa et al., 2009; 
Ren et al., 2015) have been observed in vitro in response to DON exposure. Taken together, 
evidence suggests that DON not only increases oxidative damage but also inhibits mechanisms 
that protect against oxidative stress, likely increasing the oxidative capacity of DON. Moreover, 
oxidative damage by DON can lead to cell death as evidenced by increased apoptosis in chicken 
splenic lymphocytes (Ren et al., 2015) and strong upregulation of pro-apoptotic genes following 
DON exposure (Benassi et al., 2012; Li et al., 2014; Ren et al., 2015). Comparable apoptotic 
effects have been seen in vivo where Taiwan country chickens, after a 16-week dietary exposure 
to DON, showed increased apoptotic cells and DNA damage within the spleen (Chen et al., 
2017). 
While estrogenicity is the most recognized mode of ZEA toxicity, not all adverse effects 
can be solely attributed to estrogenicity alone (Abid-Essefi et al., 2004). In fact, oxidative 
damage is a contributing pathway for ZEA toxicity (Hassen et al., 2007), although exact 
mechanisms for ZEA-induce oxidative stress are not yet established (Zinedine et al., 2007). 
Mitochondrial dysfunction was strongly implicated in ZEA toxicity where exposure of chicken 
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splenic lymphocytes to ZEA resulted in altered calcium homeostasis, intracellular acidification 
and eventual apoptosis (Wang et al., 2016). ZEA was also found to target mitochondria in human 
colon cells and this effect was linked to other observed effects of ZEA including increased lipid 
peroxidation and cell death and inhibition of protein and DNA synthesis (Kouadio et al., 2005). 
Numerous other in vitro studies have reported similar oxidative effects of ZEA including 
inhibited cell proliferation and increases in ROS production, apoptotic cells, heat shock protein 
expression and MDA formation (Abbid-Essefi et al., 2004; El Golli-Bennour et al., 2008; 
Bouaziz et al., 2008; Abbid-Essefi et al., 2009; Lee et al., 2013). Animal studies using dietary 
exposures to ZEA support the in vitro findings. Pregnant rats fed ZEA for seven days exhibited 
decreased activity of antioxidant enzymes and increased MDA content in both serum and liver at 
all levels tested (Zhou et al., 2015). These same responses, along with increased liver weight, 
were observed in gilts following dietary exposure to low levels of ZEA (1.1 to 3.2 mg/kg) for 18 
days (Jiang et al., 2011). Only one dietary exposure to ZEA in poultry evaluated biochemical 
indicators related to oxidative stress. In this study, laying hens exposed to 7.9 mg/kg ZEA for 4 
weeks demonstrated an oxidative stress response through elevated activity of GPx in the liver 
and kidney and increased activity of g-glutamyltransferase in the plasma although no clinical 
toxicosis was observed (Gresakova et al., 2012). While the exact mechanisms by which ZEA 
induces oxidative stress are unknown, it is clear that, in the absence of overt mycotoxicosis, ZEA 
may still produce oxidative damage that sub-clinically affects the overall health of poultry. 
 
1.3.2 Immunomodulation 
In poultry, as well as other species, DON exhibits both immunostimulatory and 
immunosuppressive effects depending on the concentration of DON administered, the duration of 
exposure, and the sensitivity of the exposed species (Pestka, 2008). Generally, low concentrations 
of DON (< 5 ppm) or acute exposures stimulate the immune system whereas high concentrations 
or chronic exposure suppress it (Pestka, 2003; Swamy et al., 2004). Although immune 
modulation by DON is not completely understood, it is likely due to DON-mediated activation of 
MAPK cascades or DON-induced oxidative damage as both pathways can affect immune tissues 
and cells. The spleen, specifically, appears to be a target for DON in vivo. Increased germinal 
centers were identified in spleens of turkey poultry following dietary exposure to 3.9 mg DON/kg 
feed for up to three weeks (Girish et al., 2010). Taiwan country chickens fed 5 mg DON/kg feed 
for 16 weeks had heavier spleens which, upon histological analysis, was attributed to an increased 
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number of splenic germinal centers as compared to groups receiving lower concentrations of 
DON (Chen et al., 2017). Similarly, broiler chickens fed a low-level DON diet (1.68 mg DON/kg 
feed) displayed increased spleen weight after four weeks of exposure (Yunus et al., 2012). In this 
study, splenic changes induced by DON were accompanied by altered antibody titers in response 
to common poultry vaccines (infectious bronchitis virus and Newcastle’s disease virus). In vivo 
studies have reported an ability of DON to suppress antibody responses to vaccines for both 
infectious bronchitis virus (Ghareeb et al., 2012) and Newcastle’s disease virus (Dänicke et al., 
2003) in poultry. In a recent study, broilers fed a diet naturally contaminated with a complement 
of Fusarium toxins, including DON, had reduced IgA, relative spleen weight, and antibody titers 
against NDV (Li et al., 2012). The same study found that DON also modulated the expression of 
various pro- and anti-inflammatory cytokines in the spleen. Within cells, DON modifies 
intracellular transcription factors via action at the ribosome, potentially altering expression of 
chemokines and cytokines and the immune and inflammatory pathways they regulate (Zhou et 
al., 2003; Pestka, 2007). This function of DON may, in part, explain leukocytic responses to 
DON. Populations of duodenal lymphocytes and circulating monocytes were reduced and the 
metabolic burst of heterophils was increased in broilers fed 3 mg DON/kg feed for two weeks 
(Revajova et al., 2013). In broiler chicks fed 3 mg DON/kg feed for four weeks, a similar increase 
in circulating heterophils was noted (Levkut et al., 2009). Feeding of naturally DON-
contaminated diets over a longer period (eight weeks) was found to decrease B- and T-cell counts 
in broilers (Swamy et al., 2004). In addition to direct effects on immune tissues and cells, 
Antonissen et al. (2014) found that intake of DON-contaminated feed (3 – 4 mg DON/kg feed) 
and subsequent damage to intestinal mucosa was a pre-disposing factor for the development of 
bacterial disease in broilers. Thus, low-level DON contamination, while not directly responsible 
for disease, can reduce efficiency of production and increase susceptibility to disease.  
While immunotoxic mechanisms of ZEA have not been fully elucidated, it is likely that 
ZEA toxicity to the immune system can be conferred in multiple ways. Firstly, ZEA is 
structurally similar to estrogen and the immune system is sensitive to estrogenic compounds due 
to the fact that many immune cells possess estrogen receptors. Estrogenic compounds, like ZEA, 
can be immunostimulatory or immunosuppressive depending on the dose and timing of exposure 
(Igarashi et al., 2001). Secondly, ZEA also possesses an oxidative capacity (reviewed above) and 
highly-proliferating cells, such as immune cells and tissues, are susceptible to oxidative stress 
(Bony et al., 2006; Pinton and Oswald, 2014). Indeed, in vitro treatment with ZEA increased 
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markers of lipid peroxidation and activity of acetylcholinesterase in isolated broiler lymphocytes 
(Lautert et al., 2014). Exposure to ZEA has also been shown to alter mRNA expression of 
cytokines in chicken splenic lymphocytes in vitro (Wang et al., 2012) as well as in pig spleens 
following 18-day dietary exposure (Pistol et al., 2015). Immune responses to ZEA in vivo appear 
to be immunostimulatory. Specifically, lymphoid infiltration of the liver has been observed in 
both mice (Abbès et al., 2006a) and swine (Jiang et al., 2010) consuming ZEA contaminated 
diets. Dietary exposure of goats to low-level ZEA-contaminated diets (2.4 mg ZEA/kg body 
weight) also resulted in hepatic lymphoid infiltration, which was associated with increased 
expression of estrogen receptors in the liver (Dong et al., 2010).  
 
1.3.3 Lipid utilization and metabolism 
The liver is a highly metabolic organ and is partially responsible for the detoxification of 
ingested mycotoxins, including DON and ZEA. However, to maintain metabolic function, the 
liver requires constant cell turnover and, as one of the first organs to encounter unmetabolized 
DON and ZEA, the liver is also susceptible to their toxic effects. The liver plays an important 
role in lipid metabolism, storage, and distribution, and all of these processes can be disrupted by 
DON or ZEA to affect lipid homeostasis. Serum concentrations of total cholesterol and 
triglycerides were elevated in mice fed very low doses of DON (45 μg/kg body weight/day) for 
seven days (Kouadio et al., 2013). Apart from this study, DON-associated impacts on lipid 
metabolism appear to manifest in the liver. Dietary exposure to DON significantly increased total 
lipids in livers of carp (Pietsch et al., 2014; 953 μg DON/kg feed) and total cholesterol and 
triglycerides in livers of laying hens (Farnworth et al., 1983; 0.35 mg DON/kg feed). A single 
dose of DON (2 μg DON/g egg weight) administered in ovo to chicken embryos (embryonic day 
12, ED12) resulted in accumulation of fatty droplets in the liver (Moon et al., 2007).  
Altered lipid profiles have been observed following in vivo exposure to ZEA. Blood 
triglycerides and hepatic lipids were increased in mice exposed to 200 μg DON/day over 14 days 
(Nogowski, 1996). In this case, increased blood triglycerides were attributed to the actions of 
insulin; however, insulin does not promote lipid accumulation, so this effect was hypothesized to 
be due to anabolic activity of ZEA. Pigs receiving 1.3 mg DON/kg feed for 24 days 
demonstrated elevated cholesterol, high-density lipoprotein, and reduced triglycerides in serum 
(Jiang et al., 2010). While this study offered no direct mechanism of action, the potential 
estrogenic metabolic effect of ZEA was suggested. A single dose of ZEA (40 mg ZEA/kg body 
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weight) significantly reduced levels of total cholesterol, triglycerides and high- and low-density 
lipoproteins in the serum of mice (Abbès et al., 2006b). Unlike previous studies, Abbès et al., 
(2006b) postulated that effects of ZEA on the lipid profile resulted from ZEA-induced liver 
stress rather than estrogenic effects of ZEA. Overall, the effects of ZEA on lipid metabolism has 
not been investigated in poultry but based on results in other animals ZEA could potentially alter 
lipid metabolism via estrogenic or oxidative pathways.  
 
1.3.4 Combined toxicity of DON and ZEA 
Together, DON and ZEA comprise one of the most frequently detected combinations of 
mycotoxins (Smith et al., 2016), yet relatively little is known about their interactive toxicity. 
Studies conducted with cell lines indicate that DON and ZEA behave both additively and 
synergistically but have limited estrogenic effects. Swine jejunal epithelial cells exposed to a 
combination of DON and ZEA were found to have decreased cell viability, despite the fact that 
the individual doses of each mycotoxin were non-cytotoxic (Wan et al., 2013). In human colon 
cells, DON and ZEA demonstrated a nearly-additive reduction in cell viability (Kouadio et al., 
2007). Lymphocyte proliferation was also reduced in an additive and dose-dependent manner in 
human and rat cell lines (Atkinson and Miller, 1984). In a study by Sun et al., (2015), synergistic 
interactions were reported between aflatoxin B1 (AFB) and DON, as well as AFB and ZEA in rat 
liver cells and these combinations decreased cell viability through increased production of ROS 
and induction of apoptosis, as indicated by up-regulation of caspases and down-regulation of an 
anti-apoptotic gene. The combined toxicity of DON and ZEA was not investigated in the 
aforementioned study; however, potential interaction between DON and ZEA is suggested by 
similar interactions with AFB. Regarding estrogenic effects, Pizzo et al. (2016) found no 
interactive effects of the two toxins on cell proliferation or steroidogenesis in bovine ovarian 
cells.  
There are several in vivo studies that suggest that DON and ZEA together can have 
adverse effects on the immune system of animals. In a study by Pestka et al. (1987), exposure to 
DON and ZEA together reduced resistance to infectious bacteria, Listeria monocytogenes, in 
mice to a greater extent than DON alone, while Liang et al. (2015) found that mice receiving 
intraperitoneal injections of the combination displayed sub-additive nephrotoxic effects. In the 
latter study, the exposure was found to increase the rate of apoptosis and increase indicators of 
renal oxidative stress (serum creatine and urea). Conversely, when mice received the 
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combination of DON and ZEA orally, the effect of DON and ZEA was determined to be 
antagonistic regarding lipid peroxidation and anti-oxidant capacity in the liver and synergistic 
regarding hepatic mRNA expression of pro-apoptotic genes (Sun et al., 2014). An early report in 
weanling mice found no synergistic or antagonistic effect of DON + ZEA feeding on organ 
weights and immune function (Forsell et al., 1986). However, this study did not indicate whether 
additive effects were present and endpoints to evaluate immune function were limited. Among 
livestock, swine are regarded as one of the most sensitive species to mycotoxins. Pigs fed 
naturally contaminated diets displayed decreased growth performance, increased oxidative DNA 
damage and increased liver hydropic degeneration in response to a combined DON and ZEA 
exposure compared to a non-exposed group; however, no contrast between individual 
mycotoxins and the combination was offered (Weaver et al., 2014). Young pigs fed low-levels of 
DON (0-3.0 mg/kg) and varying concentrations of 15-ADON and ZEA exhibited metabolic 
effects including, decreased skin temperature, feed intake, and thyroid size in addition to a 
delayed immune response (Rotter et al., 1994). Even at very low levels (μg/kg body weight 
range), pigs fed the combination of DON and ZEA showed increased lymphocytes, plasma cells, 
and macrophages in the lamina propria of the gastrointestinal tract – however these immune 
effects were not considered to be additive or synergistic (Lewczuk et al., 2016). In broiler 
chickens, intake of both high and low levels of DON and ZEA resulted in decreased peripheral 
lymphocytic and phagocytic cell populations; however, again, this study did not contrast 
individual effects of DON or ZEA with their combinatorial effects (Levkut et al., 2011).  
 
1.4 Challenges evaluating mycotoxin toxicity 
1.4.1 Inter- and intra-species sensitivity 
Not all species are equally susceptible to the effects of mycotoxins, making it difficult to 
extrapolate conclusions based on toxicity data from one species to another. For example, the 
widely documented sensitivity of animals to DON from most to least sensitive is ranked as 
follows: pigs > mice > rats > poultry ≈ ruminants (Prelusky et al., 1994). Differences in 
sensitivity are generally attributed to the varying types of gastrointestinal systems (i.e. 
monogastric vs. ruminants, hindgut vs. foregut fermenters) which contribute to varying 
mycotoxin toxicokinetics (i.e. absorption, distribution, metabolism and elimination). Depending 
on the toxicokinetic mechanisms employed by a species, mycotoxins can either be 
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biotransformed to bioactive (more toxic) or inactive (less toxic) metabolites, which confer 
increased or decreased sensitivity, respectively.  
In poultry, there is wide variability in species-specific sensitivity to mycotoxins. For 
example, turkeys have shown greater sensitivity to DON as compared to chickens in part due to 
slower excretion of DON and its metabolites (Schwartz-Zimmerman et al., 2015) and ZEA 
(Devreese et al., 2015) when compared to chickens. Similarly, greater susceptibility of turkeys to 
ZEA is attributed to the predominant hepatic metabolism of ZEA towards the production of a 
bioactivated metabolite (α-ZEL) when compared to metabolic capacity of chickens (Devreese et 
al., 2015). Even within a single poultry species, comparing responses to mycotoxins can be 
complex. Broiler and layer chickens, despite their genetic proximity, have been consistently bred 
for different purposes and thus, differ greatly in their physiology and their metabolic capacity 
(Buzala et al., 2015). Huff et al. (1986) concluded that the rapid growth of broilers made them 
more sensitive to growth rate inhibition induced by DON, as compared to layers. Differences in 
susceptibility to DON is also reported among broiler breeds. Earlier studies using the Hubbard 
strain found that a diet containing greater than 15 mg DON/kg feed was required to affect growth 
performance (Huff et al., 1986; Kubena et al. 1988, 1989). However, more recent studies in 
Lohmann (Dänicke et al., 2003) and Ross (Swamy et al., 2004; Yunus et al., 2012; Ghareeb et al., 
2014) strains have found reduced performance at DON levels ranging from 7 to 12 mg DON/kg 
feed and this difference was again attributed to faster growth. Yunus et al. (2011) postulated that 
improved growth rate and feed efficiency in modern broilers decreases their threshold for 
mycotoxin-induced effects on growth performance. While less information is available with 
regard to chicken sensitivity to ZEA, it is likely that these differences, as well as the genetic and 
microbial diversity that may occur in one flock, have potential to contribute to variability in 
toxicity and make it difficult to compare findings across studies or apply them to a production 
setting.  
 
1.4.2 Experimental design and modelling 
The type of experimental model or certain factors of experimental design can affect the 
outcome of mycotoxin toxicity studies. In vitro methods are useful for evaluating effects on 
specific cells or tissues, but it is difficult to accurately account for systemic influences, like 
toxicokinetics, that can increase or decrease the potency of mycotoxins. Moreover, these studies 
are generally only conducted over short periods of time (i.e. 24 to 96-hour exposures) and do not 
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reflect a chronic exposure. Conversely, in vivo methods present another unique set of challenges. 
When formulating diets for in vivo mycotoxin exposures, one must focus not only on the 
mycotoxin content of the diet but also on ensuring the contaminated diet is ingested, which can 
be difficult as many mycotoxins are known to impact feed intake (Eriksen and Petterson, 2004). 
Force-feeding is the only way to eliminate this variation in feed intake in vivo; however, this 
practice presents serious welfare concerns. In addition, duration and level of exposure can 
influence the severity of effects observed with dietary mycotoxin exposure. In terms of 
immunity, responses to low concentrations of DON or acute exposures are often associated with 
immune stimulation, while those induced by high concentrations of DON or chronic exposures 
are more in line with immune suppression (reviewed in Pestka, 2008). In a study by Wang and 
Hogan (2018), broiler chickens were more sensitive to the adverse effects of DON on growth 
performance in the latter part of the production cycle (grower phase), demonstrating that timing 
of exposure with regard to developmental stage can also influence experimental outcomes.  
The use of either artificially or naturally mycotoxin-contaminated diets in animal trials 
can also influence the degree of toxicity. Because mycotoxins rarely exist independently of one 
another within feeds (Schatzmayr and Streit, 2013; Smith et al., 2016; Biomin, 2017), there is 
risk of mycotoxin synergism or additivity in feeds that are formulated with naturally-
contaminated grain. While this situation is more reflective of feed used in commercial production 
systems, interactive toxicity can lead to unintentional over- or under-estimation of mycotoxin 
toxicity when the diet is referred to as mono-contaminated (i.e. referred to as “DON-
contaminated” when smaller quantities of other mycotoxins are also present).   
 
1.4.3 Analyzing interactive toxicity 
As previously stated, animal feed is particularly vulnerable to contamination by multiple 
mycotoxins and studying their interactive toxicity provides more relevant information to the 
livestock industry. Interactions between mycotoxins are inferred when a mixture of mycotoxins 
produces a biological response that is greater (synergistic) or lower (antagonistic) than expected 
based on their individual toxicities. Interactions can also be defined as potentiative when one or 
both of the mycotoxins in a binary mixture does not induce an effect whereas the combination 
induces a significant response. When the effect induced by a mycotoxin combination is equal to 
the sum of their individual effects, this is considered additivity (which is a non-interaction 
effect).  
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Currently, the three main approaches to analyzing interactive toxicity are 1) the 
arithmetic definition of additivity, 2) factorial designs, and 3) the theoretical biology-based 
methods (Alassane-Kpembi et al., 2017). In their review of combinatorial mycotoxin research, 
Alassane-Kpembi et al. (2017) determined that most studies relied on arithmetic definitions of 
additivity to determine interactive toxicity of mycotoxins. With this approach, combined effects 
of mycotoxins are arithmetically contrasted to the individual (expected) effects and values that 
are not significantly different, or that are above or below the expected values, are interpreted as 
additive, synergistic, or antagonistic, respectively. This is not considered a robust method as it 
does not provide a reasonable reference point for interactivity (Boedeker and Backhaus, 2010; 
Alassane-Kpembi et al., 2017). In contrast, theoretical biology-based methods (Bliss’ 
independent criterion, Loewe’s additivity model, the Chou-Talay method, and isobolograms) 
allow researchers to determine the presence of an interaction, the type of interaction and, 
optionally, the interaction magnitude. These models, while considered very biologically 
plausible, require researchers to determine a median-effect dose (i.e. IC50 or EC50) for measured 
endpoints. In vivo, median-effect doses would need to be determined for each measured 
parameter as they are likely to differ greatly across endpoints in a whole animal system. 
Therefore, this approach is not feasible for in vivo experimentation. The most robust method for 
determining in vivo mycotoxin interactions, thus far, is the factorial design method as it allows 
researchers to test a true, statistical departure from additivity. Unfortunately, the nature of 
interaction with regard to additivity, synergism or antagonism cannot be determined with this 
approach and has to be inferred indirectly (Bhat and Ahangar, 2007). A factorial design applied 
to animal feeding studies can also be costly, resource intensive and use large numbers of animals 
as each mycotoxin in the mixture must also be tested individually.  
 
1.5 The chicken embryo as an alternative animal model for mycotoxin research 
Discerning the effects of nutritional toxins can be a complex process and mycotoxins are 
no exception. When studying mycotoxins and their interactions in vivo, the process is further 
complicated by the inherent variability surrounding whole animal (in vivo) models. Considering 
the limitations of both in vitro and in vivo research (described in the sections above), alternative 
models for characterizing mycotoxin toxicity should be explored. The developing chicken 
embryo, or in ovo model, maintains the benefits of both in vitro and in vivo modelling by 
providing a whole animal system within the isolated environment of the egg. Compared to in 
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vivo models, the nutritional self-sufficiency of the chicken embryo and direct administration of 
test compounds in ovo greatly limits the sources of variation previously discussed. Therefore, 
this model, being a whole organism, could achieve similar objectives to the in vivo model but its 
use would greatly improve the efficiency of experimentation - effectively reducing the number of 
individual animals used. The chicken in ovo model is also accessible (locally or commercially), 
easy to handle, and typically inexpensive, allowing researchers from a diverse set of 
backgrounds and skill levels to utilize them (Bjørnstad et al., 2015; Scanes and McNabb, 2003; 
Henshel et al., 2002). Moreover, the short incubation time of the chicken egg (~21 days) means it 
can function as a high-throughput screening model (Bjørnstad et al., 2015). Taken together, these 
characteristics allude to a favorable alternative for effectively assessing the toxicity of individual 
mycotoxins and mycotoxin mixtures on major organ systems. 
The chicken embryo is an extensively studied model and the process of its development 
is well-documented; thus, information regarding the anatomical, physiological, biochemical and 
endocrine development of many of genetic sources/breeds of chick embryos is copious (Scanes 
and McNabb, 2003). The value of in ovo testing of environmental contaminants has already been 
recognized. Toxic effects of a diverse range of pollutants, including perfluorooctanesulfonate 
(Peden-Adams et al., 2009), polychlorinated biphenyls (Carlson and Duby, 1973), 
polyhalogenated aromatic hydrocarbons (DeWitt et al., 2005), bisphenol-S (Crump et al., 2016), 
methylmercury (Heinz et al., 2006), thiurams (Korhonen et al., 1982) and bendiocarbs 
(Petrovova et al., 2009), have been successfully evaluated by using chicken embryos as wild-life 
surrogates. Additionally, established in ovo assays such as the chicken embryo screening test 
(CHEST; Jelinek et al., 1994) and the early embryo assay (EEA; Henshel et al., 1993) can be 
used to study embryotoxicity of pharmacologic compounds. These assays focus on insult during 
early embryonic development; thus, similar assays have been used to study maternally-deposited 
mycotoxins (aflatoxin B1, ochratoxin, citrinin) that appear in the egg environment during this 
time. Such studies demonstrate that the individual (Oznurlu et al., 2012; Saleemi et al., 2015; 
Monson et al., 2016) and combined (Veselá et al., 1983; Edrington et al., 1995) toxicity of 
mycotoxins can be evaluated across morphological, histological, biochemical and molecular 
endpoints in the early-stage chicken embryo. Therefore, individual and interactive effects on 
these endpoints can likely be evaluated following a late-term exposure (embryonic day 14 – 
hatch) as well. By embryonic day 14, the chicken embryo is fully formed, and the remainder of 
incubation is dedicated to growth and refinement (Figure 1.2). Mycotoxin exposure aimed at this 
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period would limit potential teratogenic effects and would provide a more suitable model for 
predicting in vivo responses to non-maternally deposited mycotoxins (like DON and ZEA). 
Moreover, embryonic development during this time is defined by production of distinct immune 
cells as well as the rapid growth and increased functionality of the gastrointestinal tract 
(Romanoff, 1960; Romanoff and Romanoff, 1972; Macalintal, 2012). Similarly, the development 
of starter phase chickens (post-hatch day 1 – 21) is characterized by rapid growth of the small 
intestine and diversification of the immune system. It is likely, then, that responses of chicken 
embryos following late-term, in ovo exposure to mycotoxins could be more easily extrapolated to 
production animals than in vitro responses to the same mycotoxins.   
 
 
 
Figure 1.2 Embryonic development of the chicken embryo throughout incubation. Number 
labels for each image indicate day of incubation or embryonic day (ED). Adapted from 
Hamburger and Hamilton (1951).  
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The chicken egg is a versatile model for toxicity testing that allows multiple routes of 
toxin exposure to be mimicked in ovo by administering test compounds to specific egg 
structures. For example, toxins applied to the shell mimic exposure to environmental 
contaminants (e.g. pesticides) (DeWitt et al., 2005) and vaporized toxins within an incubation 
chamber, post-pip, replicate the route of inhalation (Bjørnstad et al., 2015). Toxins can also be 
injected into internal egg components. Injection into the highly vascularized yolk sac allows 
researchers to imitate systemic or maternal exposure (Bjørnstad et al., 2015). In the case of 
mycotoxins, animals are exposed through the diet, thus a successful test model for combined 
mycotoxin toxicity must be able to mimic exposure via ingestion. For replicating the route of 
exposure for ingested contaminants, the toxins can be injected into the amniotic fluid of the egg 
during the last third of the incubation period (beginning embryonic day 14). Immediately prior to 
this period, the albumen sac ruptures and albumen begins to move freely into the amniotic sac 
(Oegema and Jourdian, 1974). This mixture of amnion and albumen is then orally consumed by 
embryo (Oegema and Jourdian, 1974; Henshel et al., 2002), absorbed within the gastrointestinal 
(Sugimoto et al., 1999; Moran Jr., 2007) and is metabolized as feed (Sugimoto et al., 1999; 
Bjørnstad et al., 2015). A small portion of the albumen also moves into the yolk sac, evading oral 
consumption (Moran Jr., 2007). For brevity, the term amniotic fluid will hereafter refer to the 
mixture of amniotic fluid and albumen mixture. 
In conclusion, the in ovo model is a promising intermediate between in vivo and in vitro 
approaches for evaluating the toxicity of singular and co-occurring mycotoxins. In ovo 
methodology can effectively reduce the number of animals required for individual and 
combinatorial mycotoxin exposures as compared to in vivo modelling while still retaining some 
precision of cell model exposures. This model is accessible, versatile, and due to its background 
of use in toxicity testing, the knowledge regarding the development of this model is widely 
available. While traditional in ovo assays have focused on toxin exposure at early stages of 
embryonic development, an amniotic fluid exposure targeted at development during late 
incubation would more closely resemble dietary exposure in the starter-phase chicken and 
observed physiological responses could more easily be extrapolated to practical application. 
Overall, the in ovo model could be used to rapidly-screen mycotoxins in order to predict whole 
animal responses and prioritize single mycotoxins, or mycotoxin mixtures, for future 
investigation in vivo. In the future, this model could also be used to test mitigation techniques for 
the effects of mycotoxins and elaborate on the potential detrimental effects of emerging 
 20 
mycotoxins, mycotoxin metabolites and masked mycotoxins (conjugates of well-known 
mycotoxins). 
 
1.6 Objectives and Hypotheses 
The overall objective of this thesis research is to determine whether an in ovo approach 
for conducting exposures to Fusarium mycotoxins could be used as a predictive tool for assessing 
the toxicity of Fusarium mycotoxins alone and in combination. The overall hypothesis of this 
thesis research is that responses of the late-term chicken embryo to single doses of Fusarium 
mycotoxins, alone or in combination, are similar to those reported in whole animal feeding trials 
with poultry. In order to test this hypothesis, a series of specific objectives are identified:  
 
1. To determine the impacts of a single, in ovo administration of DON to the late-term chicken 
embryo in terms of embryotoxicity, growth and development, pathological changes to tissue, 
and biochemical/molecular indicators of oxidative stress and immune response. 
2. To determine individual and interactive effects of a single, in ovo administration of DON 
and/or ZEA to the late-term chicken embryo in terms of embryotoxicity, growth and 
development, pathological changes to tissue, and biochemical indicator of oxidative stress. 
3. To compare outcomes of in ovo exposures to previous in vitro and in vivo research in poultry 
reporting individual effects of DON and the effects of DON when in combination with ZEA. 
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CHAPTER 2 
 
PATHOLOGICAL AND PHYSIOLOGICAL RESPONSES OF CHICK EMBRYOS 
INDUCED BY IN OVO EXPOSURE TO THE FUSARIUM MYCOTOXIN 
DEOXYNIVALENOL 
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PREFACE 
 
In this chapter, we examined DON toxicity in ovo by evaluating morphological, 
histopathological, functional and gene expression parameters. A single injection of purified DON 
was administered to late-term chicken embryos at five doses ranging from 0.0 – 5.0 μg DON/g 
egg weight. The chicken embryo demonstrated a clear response to DON with effects on 
immunity and oxidative stress that were comparable to previous in vivo and in vitro findings. Our 
results indicate that in ovo mycotoxin exposures can, to a certain extent, mimic dietary 
mycotoxin exposure and predict manifestations of mycotoxin toxicity in vivo. 
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2.1 Introduction 
Infection of cereal grains by Fusarium fungi is a major cause of plant diseases in crops 
worldwide. Apart from losses in grain yield and reduction in seed quality, the major concern 
with fungal infection is the associated contamination of food and feed ingredients by toxic fungal 
secondary metabolites, known as mycotoxins. Fusarium mycotoxins elicit acute and chronic 
toxicity and as such, pose a significant risk to human and animal health, resulting in substantial 
economic losses within the animal production sector (Hussein et al., 2001). Mycotoxins present 
in raw food and feed commodities cannot be eliminated through typical processing methods and 
often end up in finished food products and livestock diets (Sugita- Konishi et al., 2006; 
Bullerman and Bianchi, 2007; Grenier and Oswald, 2011). The fusario-mycotoxin 
deoxynivalenol (DON), produced mainly by F. culmorum and F. graminearum, is acknowledged 
as the most abundant mycotoxin globally (Rodrigues and Naehrer, 2012). In a global survey of 
feed and raw feed materials, DON was found to be the most prevalent mycotoxin, appearing in 
55% of all samples tested (Streit et al., 2013). 
Poultry are considered to be somewhat resistant to DON, in part due to rapid clearance 
and low bioavailability of DON at the tissue level (Prelusky et al., 1986). Additionally, 
metabolism of DON to non-toxic metabolites has been linked to anaerobic fermentation. Indeed, 
DON incubated with large intestine fluids (colon and ceca) from laying hens is largely detoxified 
or biotransformed (Lun et al. 1988; He et al. 1992). The recommended limit for DON inclusion 
in poultry diets is among the highest for production animals at 5 ppm, while limits for other 
monogastrics, such as humans and swine, are restricted to 1 ppm (CFIA, 2015; European 
Commission 2006; FDA 2012). Despite the observed tolerance of poultry to DON, there is 
evidence that poultry species respond adversely to feed at inclusion levels below 5 ppm (Awad et 
al., 2006; 2011; 2013; Antonissen et al., 2014). This may be a result of interactions between co-
occurring mycotoxins, the presence of undetectable toxic metabolites or masked mycotoxins, or 
be due to subclinical manifestations of DON toxicity.  
The toxicity of DON is attributed to its potent inhibition of protein, RNA and DNA 
synthesis (Rotter et al., 1996). At the ribosome, DON is able to bind the 60S unit and initiate an 
MAPK cascade, ultimately inducing apoptosis as a part of the ribotoxic stress response 
(reviewed in Pestka, 2007). Thus, tissues that require a high level of protein turnover, such as the 
gut, immune tissues and the liver, are particularly susceptible to DON toxicity (Bondy and 
Pestka, 2000; Döll et al., 2003; Pinton and Oswald, 2014) and are among the first tissues to 
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encounter any unmetabolized, undetoxified DON which also increases their exposure (Smith et 
al. 2016). Organ-specific susceptibility to DON has been reflected in vivo where broiler chickens 
fed a low-level DON diet (1.68 mg/kg) exhibited increased liver and spleen weight during week 
two and four of exposure, respectively (Yunus et al., 2012). These changes were accompanied by 
a concurrent elevation in antibody titers to common poultry vaccines demonstrating immune, as 
well as organ, sensitivity to DON. Immunomodulation by low-level DON exposure was 
demonstrated in broilers where duodenal lymphocytes and circulating monocytes were reduced 
and the metabolic burst of heterophils was increased following a two-week feeding of 3.0 mg/kg 
DON-contaminated diet (Revajova et al., 2013). Beyond direct immune effects, intake of DON-
contaminated feed and subsequent damage to intestinal mucosa was also shown to be a pre-
disposing factor for the development of bacterial disease in broilers (Antonissen et al., 2014). 
Thus, low-level DON contamination, while not directly responsible for disease, can reduce 
efficiency of production and increase susceptibility to disease. DON is also able to alter 
intracellular transcription factors through the ribosomal pathway and, in turn, modify expression 
of chemokines and cytokines and the subsequent immune and inflammatory pathways they 
regulate (reviewed in Pestka, 2007). Reduced spleen weight, IgA levels and splenic mRNA 
expression of cytokines were observed in broilers fed a diet naturally contaminated with a 
complement of Fusarium toxins, including DON (Li et al., 2012). Increased concentrations of 
reactive oxygen species (ROS) and apoptotic proteins were also observed in chicken splenic 
lymphocytes exposed to DON in vitro (Ren et al., 2015).  
While contamination of feeds with low and moderate levels of DON is a significant 
health concern for livestock production, most experimental in vivo studies examining DON 
toxicity in poultry show highly variable effects of DON on growth performance, gastrointestinal 
health and immune function (Awad et al., 2011; Yunus et al., 2012; Awad et al., 2013; Ghareeb 
et al., 2015). Differences in species, breed, developmental stage, feed composition, mycotoxin 
profile, exposure timing and duration may all contribute to variability across poultry studies. 
Many mycotoxins also influence feed intake, which makes consistent exposure difficult to 
control even within a single feeding trial. Thus, typical in vivo endpoints are subject to the 
inherent variability when using a whole animal model and may not be sensitive indicators of 
DON toxicity. Interpretation of results can be further confounded when considering potential 
interactions among co-occurring mycotoxins in naturally contaminated diets. Data obtained 
through in vitro modelling is typically used to predict interactions of mycotoxins (Ruiz et al., 
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2011; Benassi et al., 2014; Clarke et al., 2014; Alassane-Kpembi et al., 2017), but in vitro 
responses do not completely agree with those observed in vivo (Tiemann and Dänicke, 2007). 
While they can provide useful information on mechanisms of action and have less variability in 
measured endpoints when compared to in vivo models, in vitro models are also void of potential 
systemic interactions that may, through microbial or enzymatic action, influence the toxicity of a 
mycotoxin and thus, do not completely reflect the complexity of a whole animal response.  
The chicken in ovo model is an under-utilized tool in the study of mycotoxin toxicity to 
poultry. The chicken embryo has been widely, and successfully, used as a non-animal alternative 
to evaluate the toxicity of environmental pollutants, including perfluorooctanesulfonate (Peden-
Adams et al., 2009), polychlorinated biphenyls (Carlson and Duby, 1973), polyhalogenated 
aromatic hydrocarbons (DeWitt et al., 2005), bisphenol-S (Crump et al., 2016), methylmercury 
(Heinz et al., 2006), thiurams (Korhonen et al., 1982) and bendiocarbs (Petrovova et al., 2009). 
Early embryo bioassays have been used to study mycotoxins that are maternally deposited in the 
egg (e.g. aflatoxin, ochratoxin and citrinin) and the potential toxicity they confer to the embryo 
during development. Adverse effects of these mycotoxins (alone or in combination) on 
developing embryos and hatching chicks are evaluated through occurrence of embryonic 
malformations, hatch parameters, morphology and histopathology of target organs, biochemical 
and molecular markers, and post-hatch growth (Edrington et al. 1995; Veselá et al. 1983; 
Oznurlu et al. 2012; Saleemi et al. 2015; Monson et al. 2016). Mid-term (embryonic day 11) in 
ovo exposure was used to develop a toxic profile for the fusario-toxin, butenolide (Wang et al., 
2008; 2009). Although carry-over of DON from feed to the fertilized egg is negligible (Valenta 
and Dänicke, 2005), in ovo administration of DON during late term embryonic development 
could be used as a screening tool to test the combinatorial effects of mycotoxins and potential 
mitigation strategies. Embryonic development during this time is defined by production of 
immune cells and the rapid growth and increased functionality of the gastrointestinal tract 
(Romanoff, 1960; Romanoff and Romanoff, 1972; Macalintal, 2012), organ systems that are 
particularly sensitive to DON toxicity in growing birds. In fact, the development of chickens 
during the starter phase (post-hatch day 1 – 21) is similarly characterized by rapid growth of the 
gut and diversification of the immune system.  Thus, results derived from DON exposure to late-
term chicken embryos could serve as an intermediate between in vitro and in vivo models to 
better inform whole animal studies. 
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The aim of the present study was to gain a comprehensive understanding of DON toxicity 
in ovo and evaluate the validity of this model as an intermediate by comparing responses of the 
chick embryo to DON effects in vivo in previous poultry studies. To this end, analyses included 
evaluation of apical (hatch parameters, organ morphology), structural (liver and spleen 
histology), and functional (thiobarbituric acid reactive substances assay; TBARS assay) 
endpoints. Furthermore, genes related to oxidative stress and immunity were evaluated in the 
liver and spleen, respectively, to determine potential mechanisms of DON toxicity. 
 
2.2 Materials and Methods 
2.2.1 Eggs and treatment procedure 
Two-hundred thirty fertilized Lohmann LSL x Bovan (female x male) eggs were obtained 
from the University of Saskatchewan layer flock and housed at the Poultry Research Centre at 
the University of Saskatchewan. All eggs were weighed prior to set (start of incubation). Set 
(ED1) began within 24 hours of lay for all eggs. The incubator was maintained at 37.5 ºC and 
60% humidity from ED1 to ED14. At ED14, eggs were removed from the incubator and candled 
to identify unfertilized eggs or early dead embryos. Eggs containing live embryos were utilized 
for in ovo exposure via amniotic fluid injection. 
Purified DON (CAS # 51481-10-8; purity > 98%) and dimethyl sulfoxide (DMSO; CAS 
# 67-68-5) were purchased from Sigma–Aldrich Corporation (St. Louis, MO, USA). Solutions of 
purified DON were prepared at concentrations of 0.04, 0.2, 1.0 and 5.0 μg DON/μL in 10% 
DMSO. Each viable embryo was randomly allocated to one of six treatment groups (n=30): four 
DON treatment groups, an untreated control group (CON) and a vehicle-injected control group 
(DMSO) administered only the vehicle solution of 10% DMSO in purified water. On ED14, each 
solution was administered at a volume of 1 μL/g of egg weight (measured on ED1) such that 
eggs received 0.0, 0.04, 0.2, 1.0 or 5.0 μg DON/g egg weight. These groups will hereby be 
referred to as DMSO, DON 0.04, DON 0.2, DON 1.0, and DON 5.0, respectively. Immediately 
preceding injection, egg surfaces were disinfected with a 70% ethanol solution. Using a 
diamond-tipped Dremel tool, a hole was drilled in the shell at the air cell-end of each egg. The 
appropriate solution was drawn using a 200-μL pipette fitted with a sterile gel-loading tip 
(VWR), inserted into the hole at an ~45º angle and released into the amniotic fluid of the egg. 
Following injection, holes were sealed with silicone rubber (GE Silicon I, all-purpose, clear). 
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Pipette tips were changed between each injected egg. Following treatment, eggs were returned to 
the incubator until ED18 at which time they were transferred to a second incubator (37.5 ºC, 
70% humidity) until ED20.  
 
2.2.2 Sample collection 
On ED20, eggs were opened and survivability was recorded for each treatment group. 
Live embryos were euthanized by cervical dislocation, individual body weight and yolk-free 
after yolk sac was removed) body weight taken to the nearest 0.01 g. Liver, spleen, and bursa 
were removed and weighed to the nearest 0.001 g. The small intestine was also removed, 
weighed and measured. The intestine was then split into its three consecutive segments: 
duodenum (attachment at gizzard to end of duodenal loop), jejunum (end of duodenal loop to 
Meckel’s diverticulum) and ileum (from Meckel’s diverticulum to ileo-cecal junction). 
Individual small intestine segments were weighed to the nearest 0.001 g and length measured to 
the nearest 0.1 cm. Density of intestinal segments was calculated as weight per unit length 
(g/cm). The whole spleen (n=15) and sections of the liver (n=15) were taken for 
histopathological analysis and fixed in 10% neutral buffered formalin. The liver section was 
taken from the bottom of the right lobe. After fixation in formalin for 72 hours, tissues were 
transferred and stored in 70% ethanol until histological processing. Whole spleen (n=15) and 
remaining liver tissue (n=15) were flash frozen in liquid nitrogen and stored at -80 ºC for 
subsequent TBARS assay (liver only) and gene expression analysis.  
 
2.2.3 Tissue histology 
Liver and spleen tissue from three treatment groups (CON, DMSO, DON 1.0, and DON 
5.0; n=6) were trimmed to fit histopathological cassettes with a clean scalpel and submitted to 
Prairie Diagnostic Services Inc. (Saskatoon, Saskatchewan) for processing, sectioning and 
staining. Briefly, liver and spleen from each individual were paired, embedded in paraffin wax, 
and sectioned by microtome to a 5 μm thickness. Resulting sections were stained by hematoxylin 
and eosin (H & E) and mounted in triplicate on slides. Slides were examined blindly by an avian 
pathologist under an Axiostar Plus light microscope (Carl Zeiss Microscopy, LLC, One Zeiss 
Drive Thornwood, NY, USA) and evaluated for appearance of abnormalities, lesions and other 
structural changes. Micrographs were obtained using an Axiocam MRc (Carl Zeiss Microscopy) 
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and Axiovision. Rel. 4.8 software (Carl Zeiss Microscopy).  
 
2.2.4 Measurement of lipid peroxidation levels 
Malondialdehyde (MDA), a product of lipid peroxidation, was quantified in liver 
homogenates using the commercially available TBARS Parameter Assay Kit (R&D Systems, 
Abingdon, UK). In preparation, 100 mg liver samples from four treatment groups (DMSO, DON 
0.2, DON 1.0 and DON 5.0; n=8) were homogenized, lysed using a Tris-Triton cell lysis 
solution, and acidified using the kit acid reagent to remove interfering proteins. The remainder of 
the assay was carried out per manufacturer’s instructions. Briefly, acidified samples were 
centrifuged at 12 000 x g for 4 minutes and supernatant was removed. Samples and dilution 
standard were run in duplicate on a clear, 96-well plate: each well contained 150 μL of standard 
or sample and 75 μL of TBA reagent. Wells were pre-read for optical density at 532 nanometers 
(nm) (Epoch 2 Microplate Spectrophotometer, Bio-Tek Instruments Inc., Winooski, VT, USA). 
The plate was covered and incubated using a dry block heater (VWR International, Mississauga, 
ON, Canada) at 50 ºC for 2 hours, at which point the first plate reading was completed (532 nm). 
Additional readings were conducted between 2 and 3 hours of incubation and ceased when 
absorbance values began to decrease. Pre-readings were subtracted from final readings to 
quantify sample contribution to absorption. Concentration of MDA was calculated using the 
calibration curve generated through standard dilution readings (as per manufacturer instruction). 
MDA concentrations were corrected to account for dilution factor and tissue weight. 
 
2.2.5 RNA isolation, reverse transcription and quantitative PCR 
Liver and spleen tissue from four treatment groups (DMSO, DON 0.2, DON 1.0 and 
DON 5.0; n=8) were analyzed for expression of genes of interest relating to oxidative stress 
(AIFM1, BAX, CASP3, CASP9, and GPx4) and immunity (IL-6 and IL-8), respectively. Total 
RNA was isolated using TRIzol reagent (Ambion, Inc., Austin, TX, USA) as per manufacturer’s 
instructions. RNA was extracted from 15 biological samples per tissue per treatment. The 
quantity and purity of RNA was assessed using a NanoDrop 2000 (NanoDrop Technologies, 
Wilmington, DE, USA) and the quality was verified on a 1% agarose gel. Following qualitative 
measurements, 10 of the total 15 samples/treatment were carried through to complementary 
DNA (cDNA) synthesis. 
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Total cDNA was prepared from 1 μg of total RNA using the Quantitect Reverse 
Transcription Kit (Qiagen, Mississauga, ON, Canada) as directed by the manufacturer. Samples 
were diluted either 5- or 10-fold to obtain working concentrations prior to quantitative 
polymerase chain reaction (qPCR).  
The expression of individual gene targets was analyzed by qPCR on a CFX96 Real-time 
C1000 Thermal Cycler (BioRad Laboratories, Hercules, CA, USA). Gene-specific primers for 
transcripts specific to oxidative stress, apoptosis and immunity were sourced from the literature 
(Table 2.1). Reactions were run at a 20 μL volume consisting of 1μL SsoFast EvaGreen 
Supermix (Bio-Rad Laboratories), 0.8 μL of both forward and reverse primer (0.4 mM), and 2 
μL input of sample cDNA at working concentrations. Samples were run in duplicate along with 
no-template control samples (RNase-free water instead of cDNA template) and a no-reverse-
transcriptase control samples (cDNA template for which water is added instead of enzyme). A 
standard curve was run on each qPCR plate, made from a pooled cDNA samples and serially 
diluted. Standard curves for all primer pairs achieved amplification efficiency of 90-110% and an 
R2 > 0.98. The relative standard curve method was used to interpolate relative mRNA abundance 
of target and reference genes within each sample. Duplicate data for each sample was averaged 
and normalized to the reference genes (GAPDH, 18S). Data was expressed as fold-change 
relative to DMSO control. 
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Table 2.1 Primers for real-time PCR gene expression analysis in domestic chicken (Gallus gallus)  
Target Name Accession Number Primer Sequence  
(5’ to 3’) 
Tissue Source 
18S 18S ribosomal RNA AF173612 F: CGAAAGCATTTGCCAAGAAT R: GGCATCTGTTTATGGTCGG liver, spleen 
Olias et al. 
2014 
GAPDH glyceraldehyde 3-phosphate dehydrogenase AI981686 
F: GGCACGCCATCACTATC 
R: CCTGCATCTGCCCATTT liver, spleen 
Antonissen et 
al. 2015 
AIFM1 apoptosis inducing factor, mitochondria-associated 1 NM_001007490.1 
F: GAAGTACAACAACGGCTGAC 
R: GAGACAGAGACAGACTTGAC liver 
Li et al. 2014 
 
BAX B-cell lymphoma 2 associated X protein XM_422067.2 
F: GTGATGGCATGGGACATAGCTC 
R: TGGCGTAGACCTTGCGGATAA liver Ren et al. 2015. 
CASP3 caspase 3 NM_204725.1 F: TGGCCCTCTTGAACTGAAAG R: TCCACTGTCTGCTTCAATACC liver Li et al. 2014 
CASP9 caspase 9 AY057940.1 F: GTGTACCAGCTGCGAGCAGACC R: GCTTTGAGGTTCCGCAGGGTCC liver Li et al. 2014 
GPx4 glutathione peroxidase AF498316 F: CAGTACAGGGGCTTCGTCTG R: CAGCCCCTTCTCAGCGTATC liver 
Haug et al. 
2014 
IL-6 interleukin 6 NM_204628.1 F: GAAATCCCTCCTCGCCAATCTGA R: GAAATCCCTCCTCGCCAATCTGA spleen 
Wang et al. 
2012 
IL-8 interleukin 8 AJ009800 F: ATGAACGGCAAGCTTGGAGCT R: TCACAGTGGTGCATCAGAATTGA spleen 
Kaiser et al. 
1999 
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2.2.6 Statistical analyses  
This study utilized a completely randomized design. Normality and homogeneity of 
variance were tested using the Shapiro-Wilk test and Levene's test, respectively. Data not 
meeting parametric assumptions were log transformed. Differences across treatment groups were 
determined using one-way analysis of variance (ANOVA) in SAS (Statistical Analysis Software, 
version 9.4, SAS Institute Inc., Cary, NC, USA). If main factor effects were significant, the 
Tukey-Kramer post-hoc test was used to differentiate means. For analysis of gene expression, 
Dunnett’s post-hoc test was used for multiple comparison to DMSO control. A value of P < 0.05 
was considered significant. All graphs were generated using Prism 6 (GraphPad Software, La 
Jolla, CA, USA). 
 
2.3 Results 
2.3.1 Embryo survivability and morphometrics 
Percent survivability of embryos for each treatment group was as follows: CON = 96.7%, 
DMSO = 90.0%, DON 0.04 = 90.0%; DON 0.2 = 93.3%, DON 1.0 = 83.3% and DON 5.0 = 
56.7%. DON treatment had no effect on total body weight at any dose; however, yolk-free body 
weight (YFBW) was decreased in the DON 5.0 group as compared to all other treatments (Table 
2.2). Relative liver and spleen weights were increased in embryos from the DON 5.0 treatment 
group as compared to all other treatments (Table 2.2).  
Livers from individuals in both the DON 1.0 and DON 5.0 treatment groups varied from 
light to dark green and spleens in the same individuals were visibly darkened and enlarged 
(Figure 2.1). This phenomenon appeared in 4% of surviving embryos in the DON 1.0 group and 
in 41% of surviving embryos in the DON 5.0 group. Weight, length and density of the intestinal 
segments (duodenum, jejunum, and ileum) were unchanged by any treatment. The weight of the 
bursa was also unaffected by treatment. 
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Table 2.2 Effect of in ovo injection of deoxynivalenol (DON, 0.04-5.0 μg/g egg weight) on 
survivability (%) and the mean (± S.E.) relative organ weights1 (g) of Lohmann LSL x Bovan 
chicken embryos prior to hatch (ED20).  
 
 Treatment 
 DMSO (vehicle) DON 0.04 DON 0.2 DON 1.0 DON 5.0 
Survivability 90.0 90.0 93.3 83.3 56.7 
Body Weight 44.64 ±0.49 43.87 ±0.49 44.37 ±0.48 43.82 ±0.52 43.08 ±0.61 
Yolk-Free 
Weight 35.23 ±0.42
a 34.12 ±0.39a 34.35 ±0.39a 33.82 ±0.45a 30.74 ±0.50b 
Organ Weights 
     
Liver 1.553 ±0.027b 1.554 ±0.027b 1.522 ±0.026b 1.562 ±0.028b 1.916 ±0.038a 
Spleen 0.034 ±0.002b 0.030 ±0.002b 0.032 ±0.002b 0.030 ±0.002b 0.065 ±0.003a 
Duodenum 0.260 ±0.008 0.276 ±0.008 0.271 ±0.008 0.249 ±0.009 0.244 ±0.010 
Jejunum 0.441 ±0.013 0.440 ±0.013 0.461 ±0.013 0.447 ±0.014 0.401 ±0.018 
Ileum 0.463 ±0.023 0.470 ±0.023 0.493 ±0.023 0.507 ±0.025 0.426 ±0.030 
Bursa 0.132 ±0.007 0.121 ±0.007 0.128 ±0.006 0.134 ±0.007 0.114 ±0.008 
1Relative organ weight = (absolute organ weight/body weight) x100 
a,bStatistical difference following one-way ANOVA and differentiation of means by Tukey-Kramer post-hoc test (p 
< 0.05) 
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Figure 2.1 Comparison of liver and spleen gross pathology from an untreated chicken embryo 
(CON) and an embryo exposed to 5.0 μg DON/g egg weight (DON 5.0) prior to hatch (ED20) 
demonstrating hepatic bile stagnation and splenic inflammation. 
 
 
2.3.2 Histopathology of liver and spleen 
The liver tissue and spleens of randomly selected individuals (n=6) from CON, DMSO, 
DON 1.0, and DON 5.0 were H&E stained and histologically analyzed. Increased 
granulopoiesis, especially around portal areas, was evident in livers from DON 1.0 (Figure 2.2: 
C, G) and DON 5.0 (Figure 2.2: D, H) individuals as compared to both the untreated (Figure 2: 
A, E) and DMSO (Figure 2.2: B, F) control groups. Granulopoietic events appeared with greater 
frequency in the DON 5.0 group (Figure 2.2: D, H), as compared to DON 1.0, suggesting a dose-
dependent response. Splenic histopathological changes were not associated with DON treatment 
(images not shown).  
Liver 
Spleen 
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Figure 2.2 Photomicrographs of H&E stained liver sections from ED20 chicken embryos 
following in ovo exposure to increasing doses of DON. Side-by-side images were captured from 
single samples at 4X (A-D) and 10X (E-H) magnification. Images shown are from untreated 
control (A, E), DMSO (B, F), DON 1.0 (C, G) and DON 5.0 (D, H) treatment groups. 
Granulopoiesis (*) can be seen increasing in frequency as DON dose increases. 
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2.3.3 Hepatic lipid peroxidation 
 A single in ovo injection of DON resulted in a significant dose-dependent increased 
concentration of MDA in liver homogenates from chick embryos (Figure 2.3) across all 
treatment groups (n=8; Figure 2.3). Hepatic MDA production following DON 0.2, DON 1.0 and 
DON 5.0 exposure was approximately two, three, and four-fold greater than that of the DMSO 
control, respectively. 
 
 
 
 
Figure 2.3 TBARS content in the chicken embryo liver following single in ovo exposure of DON 
at ED14. Values were generated using a standard dilution of known MDA concentrations and have 
been corrected to account for dilution factors and volume of tissue. Data are represented in bars 
(mean ± SEM). Data were analyzed using one-way ANOVA followed by Tukey’s post-hoc test 
for multiple pairwise comparisons. Significant differences (p < 0.05) are indicated by letter 
notation. 
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2.3.4 Gene expression in the liver and spleen 
The relative mRNA expression of genes relating to apoptosis and oxidative stress 
(AIFM1, BAX, GPx4, CASP3 and CASP9) in the liver is shown in Figure 2.4. There was no 
effect of DON treatment on the expression of AIFM1, BAX, GPx4, and CASP3 (Figure 2.4: A-
D). Embryos in the DON 1.0 group had significantly higher CASP9 expression in the liver as 
compared to DMSO group but there was no difference in CASP9 expression between DON 5.0 
and DMSO (Figure 2.4E).  
The relative mRNA expression of genes relating to immune processes (IL-6 and IL-8) in 
the spleen are shown in Figure 2.5. Expression of IL-6 was not affected by in ovo exposure to 
DON at any level (Figure 2.5A). Embryos in the DON 0.2 group had significantly higher IL-8 
expression relative to DMSO (Figure 2.5B). 
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Figure 2.4 Liver mRNA expression of oxidative stress-related genes following in ovo exposure of 
chicken embryos to deoxynivalenol (DON). Data for each gene were normalized to the expression 
control genes (GAPDH and 18S) and expressed as fold change relative to vehicle control (DMSO). 
Bars represent gene expression (mean ± SEM). Data were analyzed using one-way ANOVA 
followed by Dunnett’s post-hoc test for multiple comparisons to one control. Significant 
differences (p < 0.05) are indicated by *.  
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Figure 2.5 Spleen mRNA expression of IL-6 and IL-8 following in ovo exposure of chicken 
embryos to deoxynivalenol (DON). Data for each gene were normalized to the expression control 
genes (GAPDH and 18S) and expressed as fold change relative to vehicle control (DMSO). Bars 
represent gene expression (mean ± SEM). Data were analyzed using one-way ANOVA followed 
by Dunnett’s post-hoc test for multiple comparisons to one control. Significant differences (p < 
0.05) are indicated by *. 
 
 
2.3 Discussion 
Poultry consuming DON-contaminated diets commonly exhibit adverse physiological 
responses – most notably reduced feed intake, modified nutrient absorption, damage to the gut 
mucosa, hepatoxicity and immunosuppression or stimulation, depending on the level and 
duration of exposure. While systemic DON toxicity is most often studied using whole animal 
feeding studies, there may also be predictive value in using the chick embryo system relative to 
both in vitro and whole animal testing. In the present study, the chicken embryo, or in ovo 
model, was proposed as an intermediate between in vitro and in vivo toxicity testing of DON to 
better inform whole animal studies. As such, late-term chicken embryos were exposed via 
amniotic fluid injection to increasing concentrations of DON in solution. While not the first 
investigation of DON’s effects in ovo, this work is the first to evaluate morphological, functional 
and molecular endpoints paralleling those commonly evaluated in vivo. Based on the results 
discussed below, the chicken embryo demonstrates a clear response to DON with effects on 
immunity and oxidative stress that are comparable to previous in vitro cell assays and in vivo 
studies with poultry.  
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In ovo exposure to the highest DON level at 5.0 μg DON/g egg weight resulted in toxic 
effects in the developing chick embryo that manifested in death. Embryo survivability was 
56.7% for this group whereas the group exposed to 1.0 μg DON/g egg had 83.3% survivability 
and survivability for all other groups was 90% or greater. Increased mortality is not typically 
associated with dietary DON intake in the post-hatch chicken; for example, a 9-week exposure of 
Leghorn chickens to a high-level DON diet (18 mg/kg feed) did not increase mortality (Harvey 
et al., 1991). It is important to note that dietary exposures are based on DON per unit feed, 
whereas the majority of in ovo exposures are based on DON per unit egg weight, making it 
difficult to directly compare exposure concentrations. In the present study, DON solutions were 
administered directly into the amniotic fluid of the egg: the amniotic fluid is consumed by the 
embryo starting ED12, but consumption increases rapidly at ED14 – the time point at which 
treatment solutions of DON were administered. Therefore, to compare between studies, we must 
consider the amniotic fluid as the “feed” and convert the dose to DON per unit amniotic fluid. 
Assuming an egg weight of 65 g at set, an individual in the 5.0 μg DON/g egg weight treatment 
would have received a total of 325 μg of DON. A typical egg weight loss during incubation is 
approximately 0.3 g/day (Willems et al., 2014); thus, a 65 g egg would weigh 60.8 g at ED14. At 
this point, the amniotic fluid would compose about 30% (Willems et al., 2014) of the total egg 
mass (i.e. 18.24 g at ED 14). Based on these calculations, the concentration of DON in amniotic 
fluid for our 5.0 μg DON/g egg weight treatment group would be approximately 17.8 μg DON/g 
amniotic fluid or 17.8 ppm DON – considerably higher than the 5 ppm DON inclusion limit 
currently stipulated for poultry feed (CFIA, 2015; European Commission 2006; FDA 2012). 
Still, feeding DON at a similar level (18 mg/kg feed or 18 ppm; cited above) did not increase 
mortality in post-hatch birds, which suggests that exposure route and/or developmental 
differences in toxicokinetics contribute to disparities in the threshold levels for DON toxicity in 
the chicken embryo as compared to post-hatch birds. Within the gastrointestinal tract of adult 
chickens, DON is biotransformed to relatively non-toxic metabolites by the gut microbial 
population (Lun et al. 1988; He et al. 1992) as well as by enterocytes themselves (Schwartz-
Zimmermann et al., 2015). Although toxicokinetics of DON have not been evaluated in the 
chicken embryo, it is hypothesized that detoxification of DON by these mechanisms in ovo is 
limited. The chicken egg and embryo are considered to be sterile, thus microbial 
biotransformation of DON is not a viable DON detoxification pathway in the chicken embryo. 
Additionally, the embryo enterocyte is structurally and functionally primitive and only begins to 
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resemble adult enterocytes in the days post-hatch (Geyra et al., 2001; Roto et al., 2016) and thus, 
has little capacity to contribute to DON detoxification. Taken together, the lack of 
biotransformation by the gut microbiota and within enterocytes likely increases chicken embryo 
exposure to injected DON and may, in part, explain the increased sensitivity of this model with 
respect to mortality. 
In this study, yolk-free body weight decreased with DON administration while whole 
body weight (including yolk) was unchanged, indicating a larger yolk and smaller embryo with 
exposure to 5.0 μg DON/g egg weight. The yolk is a critical nutritional component for the 
developing embryo with approximately 90% of the total energy requirement of the chicken 
embryo fulfilled by beta-oxidation of yolk lipids (Noble and Cocchi, 1990); therefore, the 
development of the embryo pre- and post-hatch is highly dependent on the ability of the embryo 
to utilize the yolk (Yadgary et al., 2013). Our exposure period (ED14 – ED20) coincides with the 
last seven days of incubation – a stage characterized by high lipid demand wherein ~80% of the 
yolk-lipid is mobilized and absorbed to support rapid embryonic growth (Noble and Cocchi, 
1990). Increased residual yolk and decreased embryo size observed in the present study suggests 
that DON exposure altered the ability of the chicken embryo to adequately absorb and/or 
metabolize the lipid-dense yolk. Inhibited yolk absorption may be the result of DON-induced 
hepatic bile stagnation. Green discoloration of the liver, indicative of substantial bile stagnation, 
was clearly visible in DON 1.0 and DON 5.0 individuals upon necropsy demonstrating a dose-
dependent, cholestatic effect of DON on the chicken embryo. Typically, bile is produced in the 
liver and stored in the gall bladder then released into the small intestine in order to emulsify fats. 
Bile acids also appear in the yolk and yolk-sac membrane of the chicken embryo (Surai and 
Speak, 1998; Speake, 2006; Yadgary et al., 2013), serving as an emulsifier of yolk-lipids to aid 
in lipid uptake by the yolk-sac membrane. The origin of these bile acids is currently unknown; 
however, enterohepatic cycling with the yolk (Surai and Speak, 1998) and synthesis within the 
yolk-sac membrane (Yadgary et al., 2013) are suggested sources. Thus, cholestasis could impede 
the movement of bile into the yolk and ultimately reduce the absorption of yolk lipids. 
Measurement of hepatic lipid profiles could provide insight into mechanisms by which DON 
affects yolk utilization and embryo body weight - possibly via disruption of lipid metabolism. 
The effect of DON on lipid metabolism is not well-established, yet there is some evidence that 
feeding of DON-contaminated diets alters liver nutrient uptake in broilers (Dietrich et al., 2013) 
and lipid distribution in laying hens (Farnworth et al., 1983) and carp (Pietsch et al., 2014). In the 
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only other in ovo DON exposure to date, electron microscopy revealed an accumulation of fatty 
droplets in the liver of chicken embryos exposed to DON at ED12 (Moon et al., 2007). 
Moreover, hepatic total lipids in carp (Pietsch et al., 2014) and hepatic total cholesterol and 
triglycerides in laying hens (Farnworth et al., 1983) were significantly elevated following dietary 
exposure to DON. The chick liver accomplishes up to 95% of total fatty acid synthesis (O’Hea 
and Leveille, 1969) and is also a known target for DON in poultry. Given the reliance of the 
embryo on yolk lipids, altered lipid absorption and/or metabolism are hypothesized mechanisms 
for the morphometric changes and decreased survivability discussed above.  
In addition to nutrient uptake and lipid distribution, the liver is responsible for 
detoxification of xenobiotics and is one of the first tissues to encounter ingested DON. In this 
study, chicken embryos exposed to the highest level of DON exhibited increased relative liver 
weight. Reported effects of DON on poultry organ weights, including the liver, are varied across 
studies and this is often attributed to differences in exposure concentration and duration (Swamy 
et al., 2004; Awad et al., 2011; Zain, 2011; Awad et al., 2013). A recent study found that 
consumption of low-level DON (< 5 mg/kg) contaminated feed increased liver weight in broilers 
(Yunus et al., 2012) but there was no mechanism proposed for this organ-level response. In the 
present study, histological analysis revealed a dose-dependent accumulation of granulocytes in 
livers of the DON 1.0 and DON 5.0 individuals. Granulopoietic events appeared with highest 
frequency and magnitude in the DON 5.0 group, suggesting that heavier livers are at least in part 
due to increased quantity of local granulocytes. Increased granulopoiesis following exposure to 
DON agrees with previous studies that report elevated circulating heterophils in broilers 
consuming DON (Levkut et al., 2011; Revajova et al., 2013). Heterophils are the most abundant 
avian granulocyte and are mobilized in response to chemotactic agents released during tissue 
damage at target organs (Maxwell and Robertson, 1998); therefore, damage to liver tissue may 
have promoted production of heterophils (i.e. granulopoiesis) observed in this study. Such tissue 
damage in the liver was evidenced in the dose-dependent increase in markers of lipid 
peroxidation (MDA) in response to DON exposure. Lipid peroxidation is a known mode of DON 
toxicity (Mishra et al., 2014) and was identified as the primary cause of liver damage in carp fed 
DON-contaminated diets (Pietsch et al., 2014). While increased liver granulopoiesis has not 
previously been observed in adult chickens fed DON-contaminated diets, increased lipid 
peroxidation is a widely reported response to DON-feeding in broiler chickens as well as 
cultured chicken cells exposed to DON in vitro (Borutova et al., 2008; Awad et al., 2014; Lautert 
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et al., 2014; Li et al., 2014; Ren et al., 2015). It is reasonable to infer that liver cell damage, due 
to lipid peroxidation, triggered granulopoiesis as both the granulopoietic and oxidative stress 
responses increased with DON concentration. There may also be a relationship between these 
cellular level effects and bile stagnation discussed earlier as liver damage is a known precursor 
for fat deposition and cholestasis.  
While the measured increase in lipid peroxidation indicates an oxidative stress response 
in the liver, hepatic mRNA expression of apoptotic and oxidative stress genes was largely 
unaltered by DON exposure at any dose. The apoptotic and oxidative mechanisms of DON 
toxicity are well-established (Mishra et al., 2014) and expression of target genes are considered 
sensitive markers of oxidative stress (Osselaere et al., 2013); thus, upregulation of pro-apoptotic 
genes (AIFM1, caspase-3, caspase-9, BAX) and downregulation of antioxidant genes (GPx4) 
would be expected. Instead, only caspase-9, an initiator caspase, was upregulated in the livers of 
embryos administered 1.0 μg DON/g egg weight. Apart from this singular change, our results 
contradict previous in vitro reports which show increased expression, concentration and activity 
of pro-apoptotic proteins following DON exposure (Li et al., 2014; Ren et al., 2015; Benassi et 
al., 2012; respectively). Moreover, Li et al. (2014) also reported increased lipid peroxidation in 
conjunction with changes in gene expression. One possible reason for this discrepancy could be 
that changes in gene expression response do not always correlate well to physiological responses 
and often precede their onset following a chemical exposure. Time-dependent reduction in 
oxidative stress markers was previously reported in broiler lymphocytes following a single 
exposure to DON, suggesting cellular compensatory mechanisms (Lautert et al., 2014). 
Therefore, there may have been up- or downregulation of genes immediately following initial 
exposure that was not detected in tissues that were sampled six days later.   
Increased spleen weight was observed in chicken embryos exposed to the highest level of 
DON. Upon necropsy, reddened and enlarged spleens indicative of splenic inflammation were 
observed in 41% of individuals in the same group. Splenic inflammation also occurred in the 
DON 1.0 group, but with reduced frequency (4%). In the chicken, the spleen is a principal organ 
of systemic immunity (John, 1994) and, like the liver, is a target for DON toxicity (Bondy and 
Pestka, 2000). Other studies have reported an increase in spleen weight in chickens fed DON-
contaminated diets (Yunus et al., 2012; Chen et al., 2017) and DON-induced changes in spleen 
weight were also described to be dependent on exposure duration with swelling during acute 
feeding and shrinkage during chronic feeding (Swamy et al., 2004). In the present study, 
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exposure of the chick embryo to DON occurred over a relatively short period (six days; ED14 - 
ED20) and swelling and inflammation of the spleen corresponded to the increased spleen weight, 
thus, our findings are in line with previous observations in adult chickens. Interestingly, there 
were no histological alterations to spleen tissue associated with DON exposure. Chen et al. 
(2017) found that dietary consumption of DON increased the number of germinal centers in the 
chicken spleen. This specific response would not occur in the chicken embryo spleen since the 
secondary lymphoid functions of the spleen, such as antigen-dependent lymphocyte 
differentiation, only begin post-hatch (John, 1994). Instead, the embryonic spleen undertakes 
granulopoiesis (John, 1994) and an immunostimulatory effect of DON would likely be directed 
toward this process. The spleen is closely linked to the liver through circulation in that blood is 
supplied to the spleen through the coeliac artery and drains into the liver from the larger hepatic 
portal vein (John, 1994). Considering the increased number of granulocytes seen in the liver, it is 
possible that DON stimulated granulopoiesis in the spleen and that splenic granulocytes were 
subsequently transported to the liver in response to DON-induced oxidative damage.  
Within the spleen, interleukin-6 (IL-6) expression was unaffected by DON treatment, 
which was surprising given the observed splenic inflammation and the ability of DON to 
modulate cytokine production in vivo (reviewed in Awad et al., 2013). It is important to note 
that, in this case, IL-6 was very lowly expressed and results were highly variable between 
individuals, perhaps making it difficult to discern DON-specific effects. Expression of 
interleukin-8 (IL-8) changes were also unexpected as upregulation only occurred at the second 
lowest DON dose administered (DON 0.2). This, while unexpected again, agrees with the 
putative dose-dependent immune effects of DON being immunostimulatory effects at low doses 
and immunosuppressive effect at higher doses (Pestka, 2008).  
In summary, our results demonstrate that the chicken embryo responds to DON exposure 
through changes related to immunity and the induction of hepatic oxidative stress. Specifically, 
we report that DON induces tissue- and cellular level responses in the embryonic liver and the 
spleen. It appears that DON’s effects in the chicken embryo are comparable to those reported in 
adult birds fed DON-contaminated diets, especially with regards to lipid metabolism, hepatic 
oxidative stress, and inflammatory immune response Based on these results, we propose the 
chicken in ovo model could be used as an alternative to study mechanisms of DON toxicity in 
poultry and, in the future, may be used in this capacity to predict whole animal responses to 
emerging mycotoxins or relevant mycotoxin combinations. Importantly, the chicken embryo 
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appears to be more sensitive to DON and comparative levels of DON in vivo and in ovo should 
be taken into consideration when using the in ovo model as a predictive tool. 
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CHAPTER 3 
 
INDIVIDUAL AND COMBINED EFFECTS OF FUSARIUM MYCOTOXINS, 
DEOXYNIVALENOL AND ZEARALENONE, FOLLOWING IN OVO EXPOSURE IN 
THE LATE-TERM CHICKEN EMBRYO 
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PREFACE 
 
In the previous chapter, we determined that physiological and pathological responses to 
the mycotoxin in ovo were conservatively predictive of in vivo DON toxicity. The objective of 
the research presented in Chapter 3 was to characterize the combined toxicity of DON and ZEA, 
administered in ovo, to the chicken embryo and compare responses in the chick embryo to those 
observed in previous combinatorial studies. As such, single injections of high (2.5 μg/g egg 
weight) and low (0.5 μg/g egg weight) doses of purified DON and/or ZEA were administered to 
late-term chicken embryos. Our results demonstrate that interactive effects of DON and ZEA 
differed across endpoints, varying from antagonistic at low doses to non-interactive or possibly 
potentiated at high doses. Additionally, independent effects of DON were consistent with those 
observed in Chapter 2.  
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3.1 Introduction 
The increasing occurrence of Fusarium fungi and associated mycotoxins in cereal grains 
is a significant issue for global agriculture. While Fusarium infection impacts the yield and 
quality of grains, consumption of mycotoxin-contaminated grains by livestock reduces overall 
productivity and health, resulting in significant economic losses to both grain and animal 
industries (Hussein et al., 2001). At present, up to 400 different mycotoxins have been identified 
and among this group exists a wide array of chemical structures and unique toxic effects 
(Berthiller et al., 2013). A confounding factor in the risk of mycotoxin toxicity is the fact that 
multiple mycotoxins, produced by one or more fungal species, can accumulate in individual feed 
commodities that compose a single diet, ultimately resulting in co-occurrence of different 
mycotoxins within feeds (Smith et al., 2016). A recent, world-wide survey of feeds and raw feed 
ingredients identified found that 71% of 18,757 samples tested contained more than one 
mycotoxin (Biomin, 2017). Based on recent meta-analyses of literature reporting mycotoxin 
occurrence in foods and feeds, the combination of deoxynivalenol (DON) and zearalenone 
(ZEA) is considered to be the most prevalent mycotoxin mixture in North America (Smith et al., 
2016) and world-wide (Streit et al., 2012). 
Dietary exposure to DON and ZEA individually is a significant health concern for 
animals and humans. As an estrogenic mycotoxin, ZEA maintains structural similarity to 
estrogen and, therefore, competes with 17β-estradiol for binding to the estrogen receptor, 
consequently interfering in fertility and reproduction (Metzler et al., 2010). Beyond its estrogenic 
impacts, numerous in vitro studies have reported ZEA’s capacity to induce oxidative stress 
(Abbid-Essefi et al., 2004; Abbid-Essefi et al., 2009; El Golli-Bennour et al., 2008; Bouaziz et 
al., 2008; Lee et al., 2013). DON is a member of the trichothecene family and ingestion of DON-
contaminated feed can cause anorexia, vomiting, and impaired immunity in various production 
animals (reviewed in Eriksen and Petterson, 2004). Within the cell, DON binds to ribosomes and 
inhibits protein synthesis through a process known as the ribotoxic stress response. This response 
can lead to apoptosis through direct activation of mitogen-activated protein kinases (reviewed in 
Pestka et al. 2007), or through oxidative stress pathways (Mishra et al., 2014). The capacity of 
DON to inhibit protein synthesis and induce apoptosis can significantly affect tissues requiring 
rapid cell turnover, such as the gut, liver, and immune tissues and cells (Bondy and Pestka, 2000; 
Pinton and Oswald, 2014).  
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While many studies report the individual toxicity of mycotoxins, in practice, the outcome 
of combined exposure may be qualitatively or quantitatively different from what would be 
predicted based on individual toxicity (Speijers and Speijers, 2004). Simultaneous exposure to 
multiple mycotoxins can result in antagonistic, additive or synergistic toxicological effects 
(reviewed in Alassane-Kpembi et al., 2017).  Despite the frequency of DON and ZEA co-
contamination, little is known about their toxic interactions. Thus far, in vitro evidence suggests 
that DON and ZEA together act additively and/or synergistically but have limited estrogenic 
effects. Swine jejunal epithelial cells exposed to a combination of DON and ZEA displayed 
decreased cell viability despite individual doses being non-cytotoxic (Wan et al., 2013). The 
effects of aflatoxin B1 (AFB) and DON together, as well as AFB and ZEA, on rat liver cells were 
synergistic in terms of oxidative stress indicators (Sun et al., 2015). Although this study did not 
explore the combination of DON and ZEA, similar hepatotoxic effects when combined with 
AFB suggest overlapping toxicity and potential for interaction. Regarding in vivo effects, dietary 
exposure of broilers to the combination of DON and ZEA at high (8.2 mg/kg + 8.3 mg/kg) and 
low (3.4 mg/kg + 3.4 mg/kg) concentrations significantly increased oxidative stress in the liver 
and decreased circulating lymphocyte and phagocyte populations (Borutova et al., 2008; Levkut 
et al., 2011). Unfortunately, in both studies, the singular and combined effects of DON and ZEA 
were not contrasted because treatment groups exposed to DON or ZEA alone were not included. 
In a mouse feeding study, DON and ZEA individually induced oxidative stress in the mouse 
kidney and, combined, their nephrotoxic effect was concluded to be sub-additive (Liang et al., 
2015); however, the interaction effect was not specifically evaluated in the statistical analyses.  
Studying mycotoxin interactions is notably complex and often require numerous 
treatment groups, as well as large sample sizes, to perform adequate dose-response analysis. The 
majority of mycotoxin mixture work is conducted in vitro, rather than in vivo, as cell models are 
less restrictive in the number of test groups (Alassane-Kpembi et al., 2017). There are also 
current ethical concerns regarding animal-based toxicity testing, which are driving the research 
and regulatory communities to find alternatives that reduce animal use (Rovida et al., 2015). 
Unfortunately, in vitro methodology fails to capture systemic interplay and using in vitro data to 
predict whole animal responses can be challenging. Considering the limitations of both in vitro 
and in vivo research, alternative models for combinatorial mycotoxin research should be 
explored. Studies using chicken embryos could be transitional between in vitro studies on cell 
cultures and in vivo experiments on whole organisms. Delivery of toxicants in ovo still results in 
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whole animal exposure, while the nutritional self-sufficiency of the chicken embryo combined 
with direct administration ensures a controlled dosing scenario, reducing the variability 
associated with mycotoxin feeding studies. Past studies have successfully used early embryo 
assays to define individual and combined toxicity of maternally-deposited mycotoxins (aflatoxin, 
ochratoxin, citrinin) (Edrington et al. 1995; Veselá et al. 1983; Oznurlu et al. 2012; Saleemi et al. 
2015; Monson et al. 2016). Previous research demonstrated that in ovo administration of DON to 
the late stage chicken embryo induced responses that were comparable to those reported for post-
hatch birds, specifically in terms of oxidative stress and immunotoxicity (Chapter 2). This 
approach may therefore also be useful for assessing adverse responses to mycotoxin mixtures, 
allowing researchers to rapidly characterize mycotoxin interactions and prioritize combinations 
for further assessment in whole animals.  
The aim of the present study was to characterize the combined toxicity of DON and ZEA 
administered in ovo to the chicken embryo and compare responses in the chick embryo to those 
observed in previous combinatorial studies. To this end, embryo and organ morphology, tissue 
structure of the liver and spleen, and hepatic lipid peroxidation were evaluated to determine the 
whole organism, tissue-level and functional responses to DON and ZEA alone and in 
combination. 
 
3.2 Materials and Methods 
3.2.1 Eggs and treatment procedure 
Three-hundred ten fertilized Lohmann LSL x Bovan (female x male) eggs were obtained 
from the University of Saskatchewan layer flock and housed at the Poultry Research Centre at 
the University of Saskatchewan. Prior to the start of incubation (set), individual egg weight was 
recorded. Set began within 24 hours of lay for all eggs and was considered embryonic day 1 
(ED1). From ED1 to ED18, the incubator was maintained at 37.5 ºC and 60% humidity. On 
ED14, eggs were candled and those that were infertile or contained early dead embryos were 
removed.  
Purified DON (CAS # 51481-10-8; purity > 98%) and purified ZEA (CAS #17924-92-4; 
> 98%) were purchased from Cedarlane (Burlington, ON, Canada) and supplied by Toronto 
Research Chemicals Inc. (North York, ON, Canada). Dimethyl sulfoxide (DMSO; CAS # 67-68-
5) was purchased from Sigma–Aldrich Corporation (St. Louis, MO, USA). Four individual 
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solutions containing purified DON or purified ZEA were prepared at concentrations of 0.5 and 
2.5 μg/μL in 20% DMSO. Two combined solutions of purified DON and purified ZEA were 
prepared at concentrations of 0.5 μg DON + 0.5 μg ZEA/μL and 2.5 μg DON + 2.5 μg ZEA/μL 
in 20% DMSO. Each aforementioned solution was administered to the corresponding treatment 
group at a volume of 1 μL/g of egg weight as measured on ED1. Treatments (n=30) included an 
untreated control group, a vehicle-injected control group (20% DMSO), 0.5 and 2.5 μg DON/g 
egg weight, 0.5 and 2.5 μg ZEA/g egg weight, 0.5 μg DON + 0.5 μg ZEA/g egg weight, 2.5 μg 
DON + 2.5 μg ZEA/g egg weight and will hereby be referred to as CON, DMSO, 0.5 DON, 2.5 
DON, 0.5 ZEA, 2.5 ZEA, 0.5 DON + 0.5 ZEA, and 2.5 DON + 2.5 ZEA, respectively. Prior to 
solution injection, egg surfaces were disinfected with a 70% ethanol solution. A diamond-tipped 
Dremel tool was used to drill a hole in the air cell end of each egg. Solutions were drawn using a 
200-μL pipette fitted with a gel-loading tip (VWR; Cat # 37001-152), the tip was inserted into 
the hole and through the membrane at an ~45º angle and the solution was released into the 
amniotic fluid of the egg. Pipette tips were changed between each injection. Holes were then 
sealed with silicon (GE Silicon I, all-purpose, clear) and eggs were returned to the incubator, 
positioned air sac up, until ED18. On ED18 the eggs were transferred to a second incubator at 
37.5 ºC and 70% humidity until ED20.  
 
3.2.2 Sample collection 
Eggs were opened on ED20 and the survivability of each treatment group was recorded. 
Surviving embryos were then euthanized by cervical dislocation and the individual body weights 
with and without the yolk (yolk-free body weight) were taken to the nearest 0.01 g. The weights 
of the liver, spleen, and bursa were taken to the nearest 0.001 g. The small intestine was removed 
and split into segments as described in Chapter 2. The weights of the individual segments were 
taken to the nearest 0.001 g and the same segments were length measured to the nearest 0.1 cm. 
Density of each segment was determined by calculate weight per unit length (g/cm). From each 
treatment group, whole spleens (n=15) and sections of the liver (bottom of right lobe; n=15) 
were taken for histopathological analysis. Tissues were fixed for ~ 72 hours in 10% neutral 
buffered formalin after which time they were transferred into 70% ethanol and stored until 
processing. Liver tissue remaining after histological sampling was flash frozen in liquid nitrogen 
and stored at -80 ºC until further analysis. 
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3.2.3 Liver and spleen histology 
Processing, sectioning, mounting and staining of tissues was conducted at the Histology 
Core Facility at the University of Saskatchewan. Briefly, liver and spleen tissue from four 
treatment groups (DMSO, 2.5 DON, 2.5 ZEA, 2.5 DON + 2.5 ZEA; n=6) were trimmed to fit 
histopathological cassettes. The liver and spleen from each individual were paired within the 
cassettes, subsequently processed, embedded in paraffin and sectioned at a 5 μm thickness. Non-
consecutive sections were mounted in triplicate on slides and stained by hematoxylin and eosin. 
Slides were examined blindly under an Axiostar Plus light microscope (Carl Zeiss Microscopy, 
LLC, One Zeiss Drive Thornwood, NY, USA). Micrographs were obtained using an Axiocam 
MRc (Carl Zeiss Microscopy) and AxioVision. Rel. 4.8 software (Carl Zeiss Microscopy). 
Histological examination of the liver and spleen focused on the detection of granulopoiesis and 
bile duct proliferation as these tissue-level changes were previously observed in DON exposed 
embryos (Chapter 2). Briefly, the quantity and size of granulopoietic events and number of bile 
duct proliferations were determined in three independent fields per section at 10x magnification. 
Identity of granulocytes and bile duct proliferations were confirmed at 100x magnification with 
an oil-immersion lens. Based on these findings, severity of each parameter in the liver and spleen 
was scored: 0 – none, 1 – minimal, 2 – mild, 3 – moderate, or 4 – severe. After a period of time, 
slides were blindly re-evaluated to validate initial findings. 
 
3.2.4 Measurement of hepatic lipid peroxidation 
TBARS, specifically MDA, were measured in liver homogenates using the commercially 
available TBARS Parameter Assay Kit (R&D Systems, Abingdon, UK). The assay was 
conducted twice on two separate plates – one containing samples from the DMSO (n=5) and low 
dose (0.5 DON, 0.5 ZEA, 0.5 DON + 0.5 ZEA; n=8) treatment groups and the other containing 
samples from the DMSO (n=5) and high dose (2.5 DON, 2.5 ZEA, 2.5 DON + 2.5 ZEA; n=8) 
treatment groups. Briefly, liver samples of ~100 mg from six treatment groups (DMSO, 0.5 
DON, 0.5 ZEA, 0.5 DON + 0.5 ZEA, 2.5 DON, 2.5 ZEA, 2.5 DON + 2.5 ZEA) were 
homogenized, lysed with a Tris-Triton cell lysis solution, and acidified using the kit acid reagent. 
Acidified samples were centrifuged at 12 000 x g for 4 minutes and the supernatant was 
removed. Samples and standard were run in duplicate on clear, 96-well plates. The plates were 
covered and incubated using a dry block heater (VWR International, Mississauga, ON, Canada) 
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at 50 ºC for two hours, at which point the first reading was completed at 532 nm using the Epoch 
2 Microplate Spectrophotometer (Bio-Tek Instruments Inc., Winooski, VT, USA). Additional 
readings were conducted in half-hour intervals until absorbance readings decreased. The 
concentration of MDA in individual samples was calculated using the formula generated from 
the standard curve and then corrected for dilution factor and tissue weight. 
 
3.2.5 Statistical analyses  
Data were analyzed in a 2 x 2 factorial design with responses to DON and ZEA 
(individually and combined) analyzed separately at the low dose (0.5 ug/g egg weight) and the 
high dose (2.5 ug/g egg weight). Normality and homogeneity of variance were tested using the 
Shapiro-Wilk test and Levene’s test, respectively. Two-way ANOVA in SAS (Statistical 
Analysis Software, version 9.4, SAS Institute Inc., Cary, NC, USA) was used to determine if 
interaction effects between DON and ZEA were significant. If interaction effects or main factor 
effects were significant, the Tukey-Kramer post-hoc test was used to differentiate means. A 
value of P < 0.05 was considered significant. Interaction graphs were generated using Microsoft 
Excel.  
 
3.3 Results 
3.3.1 Embryo survivability and morphometrics 
 Percent survivability of embryos for each treatment group was as follows: CON = 97%, 
DMSO = 97%, 0.5 DON = 93%, 0.5 ZEA = 90%, 0.5 DON + 0.5 ZEA = 97%, 2.5 DON = 93%, 
2.5 ZEA = 97% and 2.5 DON + 2.5 ZEA = 80%.  
Effects of in ovo injection of low doses of deoxynivalenol (0.5 DON) and zearalenone 
(0.5 ZEA) alone and together, on mean relative organ weights are shown in Table 3.1. Body 
weight, yolk-free body weight, and organ weights of the spleen and bursa were not significantly 
different across treatment groups. Relative liver weight was significantly higher in individuals in 
the 0.5 DON treatment groups as compared to the vehicle control (DMSO) and 0.5 DON + 0.5 
ZEA groups. Relative liver weight in individuals treated with 0.5 ZEA alone did not differ from 
any other treatment. An interactive effect was confirmed (F = 10.18, p = 0.0019) indicating an 
antagonistic effect of ZEA on response to DON in terms of relative liver weight. Weight, length 
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and density of the intestinal segments (duodenum, jejunum, and ileum) were not significantly 
different between treatments.  
Effect of in ovo injection of high doses of deoxynivalenol (2.5 DON) and zearalenone, 
(2.5 ZEA) alone and together, on mean relative organ weights are shown in Table 3.2. There 
were no significant differences in body weight or in the weight, length, and density of intestinal 
segments across treatment groups. However, there was a significant main effect of DON on yolk-
free body weight (F = 10.84, p = 0.0014). Yolk-free body weight in groups receiving 2.5 DON 
(2.5 DON, 2.5 DON + 2.5 ZEA) was significantly decreased as compared to groups receiving no 
DON (DMSO, 2.5 ZEA). There was no interactive effect of DON and ZEA on relative liver 
weight but there was a main effect of DON treatment (F = 10.43, p = 0.0017) and ZEA treatment 
(F =14.46, p = 0.0002). Relative liver weight was significantly higher in individuals administered 
2.5 DON compared to those not exposed to DON while individuals administered 2.5 ZEA also 
had higher liver weight compared to those not receiving ZEA. There was also a main effect of 
DON (F = 8.77, p = 0.0038) and ZEA (F = 4.54, p = 0.0355) on relative spleen weight with 
increased relative spleen weight in groups exposed to DON or ZEA as compared to those not 
receiving DON or ZEA. Hepatic bile stagnation paired with splenic inflammation was observed 
in 14% and 25% of surviving embryos from the 2.5 DON and 2.5 DON + 2.5 ZEA groups, 
respectively (data not shown). There was also a significant main effect of ZEA on bursa weight 
(F = 4.44, p = 0.0376). Relative bursa weight in groups receiving 2.5 ZEA (2.5 ZEA, 2.5 DON + 
2.5 ZEA) were significantly decreased as compared to groups not receiving ZEA (DMSO, 2.5 
DON).  
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Table 3.1. Effect of in ovo injection of low doses of deoxynivalenol (DON, 0.5 μg/g egg weight) and zearalenone (ZEA, 0.5 μg/g egg 
weight) alone and together on survivability (%) and the mean relative organ weights1 (g) of Lohmann LSL x Bovan chicken embryos 
prior to hatch (ED20).  
 
DON, μg/g egg wt 0  0.5  P-value 
ZEA, μg/g egg wt 0 0.5  0 0.5 SEM DON ZEA DON x ZEA 
Survivability 96.7 90.0  93.3 96.7         
Body Weight 43.80 43.09  43.05 43.83 0.31 0.9871 0.9465 0.1730 
Yolk-Free Weight 33.71 33.34  33.43 33.21 0.23 0.6719 0.5291 0.8819 
Organ Weights   
 
      
Liver 1.523b 1.561ab  1.659a 1.526b 0.015 0.0601 0.0792 0.0019 
Spleen 0.030 0.028  0.031 0.029 0.002 0.4790 0.6839 0.5831 
Duodenum 0.260 0.264  0.277 0.253 0.004 0.7132 0.3121 0.1061 
Jejunum 0.512 0.525  0.534 0.476 0.009 0.2981 0.7673 0.1033 
Ileum 0.488 0.515  0.526 0.465 0.011 0.7470 0.3669 0.1030 
Bursa 0.124 0.131  0.131 0.143 0.005 0.1312 0.1645 0.9929 
1Relative organ weight = (absolute organ weight/body weight) x100 
a,bStatistical difference following two-way ANOVA and differentiation of means by Tukey-Kramer post-hoc test (p < 0.05)  
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Table 3.2. Effect of in ovo injection of high doses of deoxynivalenol (DON, 2.5 μg/g egg weight) and zearalenone (ZEA, 2.5 μg/g egg 
weight) alone and together on survivability (%) and the mean relative organ weights1 (g) of Lohmann LSL x Bovan chicken embryos 
prior to hatch (ED20).  
 
DON, μg/g egg wt 0  2.5  P-value 
ZEA, μg/g egg wt 0 2.5  0 2.5 SEM DON ZEA DON x ZEA 
Survivability 96.7 96.7  93.3 80.0         
Body Weight 43.80 43.35  42.70 43.06 0.32 0.2179 0.9285 0.4737 
Yolk-Free Weight 33.71 33.47  32.59 31.74 0.28 0.0014 0.2134 0.4823 
Organ Weights   
 
      
Liver 1.523 1.593  1.579 1.701 0.015 0.0017 0.0020 0.3120 
Spleen 0.032 0.034  0.036 0.044 0.001 0.0038 0.0355 0.1667 
Duodenum 0.260 0.271  0.261 0.254 0.004 0.3626 0.7948 0.2405 
Jejunum 0.512 0.510  0.475 0.518 0.009 0.4199 0.2411 0.2043 
Ileum 0.488 0.498  0.489 0.485 0.010 0.7591 0.8974 0.7222 
Bursa 0.124 0.116  0.148 0.121 0.005 0.0723 0.0376 0.2555 
1Relative organ weight = (absolute organ weight/body weight) x100
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3.3.2 Histopathology of liver and spleen 
Liver and spleens in individuals (n=6) from the DMSO treatment group and the high 
mycotoxin groups (2.5 DON, 2.5 ZEA and 2.5 DON + 2.5 ZEA) were randomly selected for 
histopathological analysis. Histopathological examination of the liver did not reveal 
abnormalities (Figure 3.1). There were no major changes in liver tissue structure observed 
between the 2.5 ZEA or DMSO; however, increased granulopoiesis was observed in the 2.5 
DON group with a higher density of granulocytes appearing near portal areas (Table 3.3; 3.4). In 
the 2.5 DON + 2.5 ZEA group, frequency of granulopoietic events were increased as compared 
to DMSO, 2.5 ZEA or 2.5 DON alone (Table 3.3; 3.4). Regarding the spleen, there were no 
histopathological changes associated with treatment (images not shown). 
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Table 3.3 Scheme utilized for visual assessment and scoring of hepatic granulopoiesis in ED20 
chicken embryos following in ovo injection high doses of deoxynivalenol (2.5 μg/g egg weight) 
and zearalenone (2.5 μg/g egg weight) alone or in combination. 
 
Score Histopathological Parameters  
0 – None No evident concentrations of granulocytes 
1 – Minimal 2 – 5 small areas of concentrated granulocytes 
2 – Mild 5 – 10 small areas or 1 – 3 large areas of concentrated granulocytes 
3 – Moderate 10 – 15 small areas or 3 – 5 large areas of concentrated granulocytes 
4 – Severe >15 small areas or > large areas of concentrated granulocytes 
 
 
 
Table 3.4 Hepatic granulopoiesis scores1 of ED20 chicken embryos following in ovo injection of 
high doses of deoxynivalenol (DON, 2.5 μg/g egg weight) and zearalenone (ZEA, 2.5 μg/g egg 
weight) alone or in combination.  
 
DON, μg/g egg wt 0  2.5 
ZEA, μg/g egg wt 0 2.5  0 2.5 
1 1 0  3 3 
2 0 1  2 3 
3 1 0  3 3 
4 0 1  1 3 
5 1 1  2 3 
6 1 1  1 3 
Median 1 1  2 3 
1Scoring was based on the scheme outlined in Table 3.3 
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Figure 3.1 Photomicrographs of H&E stained liver sections from ED20 chicken embryos 
following in ovo exposure to 2.5 μg DON/g egg weight and/or ZEA. Side-by-side images were 
captured from single samples at 5X (A-D) and 10X (E-H) magnification. Images shown are from 
DMSO (A, E), ZEA (B, F), DON (C, G) and 2.5 DON + 2.5 ZEA (D, H) treatment groups. 
Granulopoiesis (*) appears with increased frequency in the DON (C, G) and 2.5 DON + 2.5 ZEA 
(D, H) groups. 
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3.3.3 Hepatic lipid peroxidation 
The effect of administration of ZEA and DON alone, and their interactions, on hepatic 
MDA is shown in Figure 3.2. There was an interactive, antagonistic effect of 0.5 DON + 0.5 
ZEA on liver MDA content (F = 8.26, p = 0.0074; Figure 3.2A). Hepatic MDA content was 
significantly higher in the 0.5 ZEA group as compared to the combined dose, 0.5 DON + 0.5 
ZEA, but neither group differed significantly from DMSO or 0.5 DON. There was no main effect 
of either DON or ZEA at this level. While there was no interactive effect of 2.5 DON and 2.5 
ZEA, there was a main effect of DON (F = 8.70, p = 0.0065) on hepatic MDA content (Figure 
3.2B). Liver MDA content was significantly higher in groups receiving 2.5 DON (2.5 DON, 2.5 
DON + 2.5 ZEA) as compared to those receiving no DON (DMSO, 2.5 ZEA).  
  
 60 
 
 
 
 
 
 
Figure 3.2 Hepatic MDA content (an indicator of lipid peroxidation) in the chicken embryo liver 
following a single in ovo exposure to 0.5 μg DON/g egg weight and/or ZEA (A) or 2.5 μg DON/g 
egg weight and/or ZEA (B). Values were generated using a standard dilution of known MDA 
concentrations and were corrected to account for dilution factors and volume of tissue. Ends of 
lines represent mean ± S.E.M. Data were analyzed using two-way ANOVA to determine 
interactive effects followed by Tukey-Kramer post-hoc test for separation of means.  
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3.4 Discussion 
Despite the frequency of mycotoxin co-contamination in feed, very few mycotoxin 
interactions have been characterized in vivo due to limitations of whole animal studies. The 
chicken embryo, or in ovo model, shows value as a conservative predictor of whole animal 
responses to DON (Chapter 2) and, therefore, could also be used to predict responses to 
mycotoxin mixtures. The present study aimed to characterize the combined toxicity of DON and 
ZEA in ovo and to compare responses in the chick embryo to those reported in other 
combinatorial studies. To this end, chicken embryos were exposed to two concentrations of DON 
and ZEA, individually and combined, via amniotic fluid injection. Endpoints that displayed clear 
responses to DON alone in previous work (Chapter 2) were evaluated in the present study. Our 
results demonstrate that interactive responses to DON and ZEA depend on the endpoint 
measured and range from antagonistic at low doses to non-interactive or possibly potentiative at 
high doses. 
At high concentrations, the combined administration of DON and ZEA was overtly toxic 
to the developing chicken embryo, resulting in embryonic death. Embryo survivability for the 2.5 
DON + 2.5 ZEA group was 80% while survivability for all other treatment groups was 90% or 
greater, including groups receiving 2.5 DON and 2.5 ZEA alone. The fact that the combination 
of DON and ZEA elicited a greater response than either individual mycotoxin at the same dose 
suggests that DON and ZEA, at high doses, may be potentiative regarding chicken embryo 
mortality. There are no prior reports in poultry where dietary exposure to DON and ZEA, alone 
or in combination, affected survival. In fact, exposure to very high concentrations of DON (70 
mg DON/kg body weight; Huff et al., 1981) or ZEA (800 mg ZEA/kg feed; Chi et al., 1980) did 
not increase mortality of poultry. Additionally, survival was not affected in mice fed high levels 
of DON (25 mg/kg) and ZEA (10 mg/kg) combined in feed (Pestka et al., 1987). In Chapter 2, in 
ovo exposure to DON alone decreased survivability of chicken embryos. It was hypothesized that 
the increased mortality was related to a lack of DON detoxification as well as DON-induced 
disruption in yolk absorption as the chicken embryo is highly dependent on yolk lipid utilization 
(Noble and Cocchi, 1990; Yadgary et al., 2013). In the present study, yolk-free body weight was 
lowered in groups receiving DON (2.5 DON and 2.5 DON + 2.5 ZEA) as compared to groups 
not receiving DON (DMSO and 2.5 ZEA), yet whole-body weight was not altered. This indicates 
that decreased embryo weight was offset by residual or unabsorbed yolk, suggesting that DON 
also inhibited or altered yolk utilization in this study. Moreover, hepatic bile stagnation, 
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demonstrated by green discolouration of the liver, was apparent in 2.5 DON-exposed groups but 
occurred more frequently in the group receiving 2.5 DON + 2.5 ZEA (25%) than the group 
receiving 2.5 DON alone (14%). While this observation is consistent with our previous findings 
(Chapter 2), it is interesting that bile stagnation was detected more often at a combined, high 
dose than either high dose of DON or ZEA individually. This again suggests that there may be 
potentiation between DON and ZEA at a high dose. It is hypothesized that bile, originating in the 
embryonic liver, moves into the yolk contents to emulsify yolk lipids during the final days of 
incubation (Surai and Speak, 1998; Speake, 2006). Thus, DON-induced (and ZEA-potentiated) 
cholestasis would impede bile movement into the yolk, decreasing absorption and potentially 
decreasing embryo weight or impacting embryo survival. 
In the present study, there was no interaction of DON and ZEA at the high dose on organ 
weights; however, both DON and ZEA alone increased liver weight of the developing chicken 
embryo. Increased liver weight has been reported in poultry with dietary exposures to DON 
(Yunus et al., 2012) and ZEA (Jiang et al., 2011). In our previous study, we found that in ovo 
exposure to DON increased liver weight and that livers displayed increased granulopoiesis 
(production of granulocytes) as observed through histological assessment (Chapter 2). In the 
present study, substantial hepatic granulopoiesis was again observed in individuals exposed to 
2.5 DON + 2.5 ZEA, as well as 2.5 DON alone, and so increased liver weight could be attributed 
to increased granulocyte production within the tissue. Granulopoietic events occurred more 
frequently in the combined exposure than with exposure to 2.5 DON or 2.5 ZEA alone, 
suggesting a potential potentiative effect of DON and ZEA at a high dose. Both DON and ZEA 
have been reported to stimulate immune cell production with in vivo exposure. Lymphoid 
infiltration of the liver, specifically, was observed in mice (Abbès et al., 2006a) and swine (Jiang 
et al., 2010) fed ZEA-contaminated diets, while broilers consuming DON-contaminated feed had 
increased number of circulating heterophils (Levkut et al., 2011; Revajova et al., 2013). When 
fed together, DON and ZEA increased the number of lymphocytes, plasma cells, and 
macrophages in the gastrointestinal lamina propria of gilts (Lewczuk et al., 2016). Heterophils, 
an abundant avian granulocyte, are highly responsive to chemotaxis and are among the first 
immune cells to arrive at damaged tissues (Maxwell and Robertson, 1998). We found that DON 
alone increased the MDA concentration in liver tissue, indicating potential liver damage by 
means of lipid peroxidation. Indeed, lipid peroxidation has previously been identified as the 
primary cause of liver damage in carp fed DON-contaminated diets (Pietsch et al., 2014). 
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Heterophils and other granulocytes may have been stimulated by DON-induced tissue damage 
resulting in the observed hepatic granulopoiesis. Furthermore, liver damage is a known precursor 
for cholestasis, thus, DON-induced tissue damage may have also contributed to the hepatic bile 
stagnation previously discussed.  
Unlike DON, ZEA’s effect on liver weight is not supported by the histopathological or 
biochemical findings. The ability of ZEA to increase liver weight independently may instead be 
attributed to its estrogenic effects. Estrogens enhanced the ability of various growth factors to 
stimulate DNA synthesis in cultured female rat hepatocytes (Ni and Yager, 1994). As previously 
mentioned, ZEA is structurally similar to estrogen and is able to bind estrogen receptors to elicit 
estrogenic effects. Through an estrogenic mechanism of action, ZEA may have enhanced liver 
growth by stimulation of growth factors. 
A high dose of ZEA alone did not alter markers of lipid peroxidation despite that fact that 
lipid peroxidation is a well-documented response to ZEA both in vitro (Abid-Essefi, 2004; Abid-
Essefi, 2009; Lee et al., 2013; Lautert et al., 2014) and in vivo (Jiang et al., 2011; Zhou et al., 
2015). The lack of effect of ZEA alone on liver granulopoiesis and lipid peroxidation may be 
related to the dose of ZEA used. Poultry are considered to be somewhat resistant to DON, yet 
they are considerably more resistant to the effects of ZEA. For example, regulatory guidelines 
are provided for DON inclusion in poultry feed, while governing bodies do not currently impose 
dietary limits for ZEA in poultry (CFIA, 2015; European Commission 2006; FDA 2012). Here, 
DON and ZEA were administered at equal concentrations and while the dose of DON 
administered incited a clear, toxic response, the equivalent dose of ZEA may not have been 
sufficient to elicit toxic interactive or independent effects with respect to granulopoiesis or lipid 
peroxidation.  
In the present study, exposure to the high concentration of DON, independent of ZEA, 
resulted in increased spleen weight. Red and enlarged spleens, indicative of splenic 
inflammation, were clearly visible upon necropsy in the 2.5 DON (14%) and 2.5 DON + 2.5 
ZEA (25%) exposure groups. These organ-level changes are consistent with our previous 
findings (Chapter 2) and can likely be attributed to an inflammatory response incited by DON at 
low doses (Swamy et al., 2004; Chapter 2). Spleen weight was also elevated, and bursal weight 
decreased in groups receiving 2.5 ZEA (2.5 ZEA and 2.5 DON + 2.5 ZEA) as compared to those 
not receiving 2.5 ZEA (DMSO and 2.5 DON). To date, these effects on spleen and bursa have 
not been reported in poultry with in vivo exposure to ZEA and could be related to the 
 64 
estrogenicity of ZEA. The immune system is sensitive to estrogenic compounds, in part due to 
the presence of estrogen receptors in immune cells (Igarashi et al., 2001). Estrogenic compounds 
can be immunostimulatory or immunosuppressive depending on the dose and timing of 
exposure. In chickens, the spleen is a principal organ of systemic immunity (John, 1994) and 
exposure to ZEA has been shown to alter mRNA expression of cytokines in chicken splenic 
lymphocytes (Wang et al., 2012) as well as increase acetylcholinesterase activity (involved in 
inflammatory responses) in broiler lymphocytes (Lautert et al., 2014). While immunostimulation 
by ZEA may have resulted in an increase in spleen weight, ZEA is also less estrogenic than 
endogenous estrogens (Metzler et al., 2010) perhaps explaining the absence of observable 
histopathological changes. The bursa, another avian immune organ, is also estrogen-sensitive. In 
particular, the embryonic bursa displays increased numbers of estrogen-responsive cells during 
the last week of incubation (Shin et al., 2012) which coincides with our treatment period (ED14 
– ED20). It is possible that the decrease in bursa weight is related to the estrogenicity of ZEA; 
however, mechanisms underlying this morphological change remain unknown.   
 At a combined low dose, DON and ZEA elicited an interactive, antagonistic effect on 
relative liver weight. Exposure to DON alone increased relative liver weight when compared to 
the vehicle control, yet, when DON and ZEA were administered together, this effect was 
diminished. Feeding diets with a combination of DON and ZEA induced hepatic oxidative stress 
in broilers (Borutova et al., 2008) and liver tissue changes in swine (Tiemann et al., 2008; 
Weaver et al., 2014; Gerez et al., 2015), and these findings along with the results of the present 
study indicate that the liver is a target for the combined toxicity of DON and ZEA. We found 
that a low, combined dose of DON and ZEA also had an antagonistic effect on lipid peroxidation 
as indicated by decreased hepatic MDA concentration. A similar antagonistic effect of DON and 
ZEA on hepatic MDA was reported in mice following a two-week exposure via oral gavage (Sun 
et al., 2014). Given the relationship between hepatic MDA and relative liver weight, it is likely 
that changes in liver weight are related to oxidative effects of DON and ZEA. DON is well-
known to elicit oxidative stress through its action at the mitochondria (reviewed in Mishra et al., 
2014). While exact mechanisms of ZEA-induced oxidative stress are unknown, mitochondrial 
dysfunction and subsequent induction of apoptosis have been implicated in ZEA cytotoxicity to 
chicken splenic lymphocytes (Wang et al., 2016). Therefore, it is possible that, at low 
concentrations, DON and ZEA act competitively at the mitochondria and suppress one another’s 
toxic effects, producing an antagonistic response with respect to oxidative stress.  
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It is interesting to note that the combined effects of DON and ZEA differ based on the 
dose of the mycotoxins administered. Here, responses range from antagonistic at the low, 
combined dose to non-interactive or possibly potentiative at the high, combined dose. In their 
review of combinatorial in vivo exposures, Grenier and Oswald (2011) determined that effects of 
mycotoxin mixtures on performance were generally additive or synergistic, but effects on other 
endpoints, including biochemical parameters, were often different for the same combination. 
Interaction dynamics similar to those in the present study have been observed following 
combined DON and ZEA exposures in vitro. Boiera et al. (2000) determined that the effect of 
DON and ZEA, together, on growth of brewing yeast differed by dose: at high doses DON and 
ZEA behaved synergistically while antagonism was observed at a lower dose. In contrast, the 
combined effect of DON and ZEA on cell viability of swine jejunal epithelial cells was 
synergistic at individually non-cytotoxic doses, but antagonistic at cytotoxic doses (Wan et al., 
2013). Neither of these studies could offer mechanistic explanations for these differences, likely 
because the understanding of ZEA’s toxic mechanisms beyond estrogenicity are limited.  
 In conclusion, our results demonstrate that interactions between DON and ZEA differ 
across endpoints measured and tend to vary from antagonistic at low doses to non-interactive or 
possibly potentiative at high doses. At low doses, DON and ZEA have antagonistic effects on 
liver weight as well as hepatic lipid peroxidation. At high doses, effects of DON and ZEA are 
mostly independent and effects of DON, specifically, are in line with our previous research. At a 
combined, high dose of DON and ZEA there is evidence of possible potentiation with respect to 
embryo survivability, hepatic bile stagnation and splenic inflammation, and hepatic 
granulopoiesis. It is important to note that suggested potentiation is purely observational. While 
the factorial analysis applied here is among the most robust statistical analyses for in vivo 
interaction studies (Alassane-Kpembi et al., 2017), it does not allow us to differentiate responses 
beyond interactive (synergistic or antagonistic) or non-interactive. Based on these results, the 
chicken in ovo model may be useful in studying the combined toxicity of mycotoxins, however, 
responses to the combination of DON and ZEA in this model, as well as other in vitro and in vivo 
models, are still variable. Further research regarding the mechanisms of ZEA-induced toxicity 
may improve the understanding of the responses observed here and in other studies.  
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CHAPTER 4 
 
GENERAL DISCUSSION 
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4.1 Project Overview and Summary of Findings 
Fusarium fungi and their toxic secondary metabolites, known as mycotoxins, are 
prevalent contaminants of cereal crops worldwide. Mycotoxins are readily found in finished feed 
and can elicit toxic effects such as reduced growth performance, altered gut health and 
compromised immunity, when ingested. Regulatory agencies have attempted to limit mycotoxin 
exposure in livestock by setting legislated or recommended limits for individual mycotoxins in 
feed (CFIA, 2015; European Commission 2006; FDA 2012). These limits, however, do not 
consider that a single feed source may contain a mixture of mycotoxins whose combined toxicity 
is likely to be additive or synergistic. At present, data on systemic effects of co-occurring 
mycotoxins are limited making it difficult to adjust current in-feed mycotoxin limits. The 
chicken embryo, or in ovo model, shows potential as screening tool for characterizing the 
systemic toxicity of mycotoxins alone and in combination, yet very few studies have employed 
in ovo methodology in the study of mycotoxins or mycotoxin interactions. In this thesis research, 
two in ovo exposures were conducted to determine the value of the in ovo model as a predictive 
tool for assessing the individual and combined toxicity of Fusarium mycotoxins. 
In the first experiment, the effects of in ovo administration of DON were evaluated. 
Results indicated that the chicken embryo responds to in ovo DON exposure with effects on 
immunity and oxidative stress that are supported by previous in vivo and in vitro findings. At the 
highest dose, DON decreased embryo survivability and increased the relative weights of the 
embryonic liver and spleen. Hepatic bile stagnation and concurrent splenic inflammation were 
also frequently detected following administration of the highest and second highest DON dose 
but were observed less often in the latter. A dose-dependent increase in granulopoiesis and lipid 
peroxidation were observed in the liver; however, mRNA expression of genes related to immune 
and oxidative stress were mostly unchanged. The in ovo approach developed and validated in the 
first experiment was then carried forward to a second experiment with the aim of characterizing 
the combined toxicity of DON and another mycotoxin, zearalenone (ZEA) administered in ovo to 
the chicken embryo. Based on the results, it was concluded that the responses to the combination 
of DON and ZEA were variable. Interactions between DON and ZEA differed across endpoints 
from antagonistic at low doses to non-interactive or possibly potentiative at high doses. At a 
combined low dose, DON and ZEA had an antagonistic effect on embryonic liver weight as well 
as hepatic lipid peroxidation. At a combined high dose, effects of DON and ZEA were mostly 
independent and effects of DON, specifically, were in line with the previous exposure to DON 
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alone. At the combined, high dose of DON and ZEA there appeared to be evidence of 
potentiation with respect to embryo survivability, hepatic bile stagnation and splenic 
inflammation, and hepatic granulopoiesis.  
 
4.2 The in ovo model as an alternative to in vivo animal testing  
The ethical concern surrounding whole animal toxicity testing is driving researchers to 
find alternatives that reduce their animal use where possible. At present, factorial design analysis 
remains the most robust approach for studying combinatorial mycotoxin toxicity in vivo. An 
important drawback of this approach, however, is that it requires many test groups and large 
sample sizes to account for the inherent variability surrounding in vivo exposures. Sources of 
variability including feed (feed composition, unidentified substances in feed) and the quantity of 
toxin ingest are difficult to control and can also contribute to a lack of reproducibility between 
seemingly similar studies. Reducing animal use in science is guided by three principles: 
replacement, reduction, and refinement. Importantly, our results demonstrate that in ovo 
responses to mycotoxins, alone and in combination, are conservatively predictive of in vivo 
responses. While in ovo experiments are unlikely to replace in vivo animal trials, they can help to 
reduce the number of animals used for mycotoxin toxicity testing. In ovo exposure allows for a 
precise dosing scenario wherein mycotoxins are directly administered into the amniotic fluid of 
the egg and are consumed entirely by the embryo during the last phase of incubation. Because 
the nutrients are already supplied to the embryo through egg components (yolk, amniotic 
fluid/albumen), this reduces variability associated with as well as quantity of ingest. Moreover, 
reduced variability and isolation within the egg means individual embryos/eggs can function as 
test units rather than groups (i.e. cage, pen, or tank) which further reduces animal use. Therefore, 
the in ovo model could be used in an integrated approach where it acts as an intermediate 
between in vitro and in vivo study to identify and prioritize emerging mycotoxins and high-risk 
mycotoxin combinations for further in vivo assessment. This would allow whole animals to be 
used only when necessary, ultimately reducing the total number of animals utilized for 
mycotoxin toxicity research.  
Beyond reducing animal usage, assessing mycotoxin toxicity in ovo can reduce costs 
associated with in vivo testing as in ovo models are relatively resource-conservative. To conduct 
an in vivo exposure, researchers must first purchase and transport whole animals which, 
depending on the species used, can be expensive. Housing space for the animals must also be 
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procured prior to their arrival. Again, depending on the species used, space requirements can be 
substantial and housing for any species must comply with production standards and/or 
stipulations set out by internal animal care committees. Stipulations may include environmental 
specifications for stocking density, airflow, water supply and quality, temperature control, 
lighting periods, and cages and bedding. A space that has both environmental controls and 
adequate capacity for whole animal may not be accessible for all researchers. In contrast, the 
space requirements for in ovo trials are minimal. During our exposures, chicken embryo/egg 
units remained within a temperature and humidity-controlled incubator that required little to no 
maintenance. Embryo/egg units were only removed once during the incubation period for the 
purposes of candling and treatment. While our trials were carried out in the university hatchery 
building, similar trials could be conducted within most lab spaces as benchtop incubators are 
becoming widely accessible. Moreover, low-cost, fertilized eggs can be obtained from 
commercial farms or university poultry science units (Henshel et al., 2002). The nutritional self-
sufficiency of chicken embryos is perhaps the most cost-effective aspect of the in ovo model. 
Feed can be a significant expense for in vivo mycotoxin exposures. Researchers must purchase a 
supply of both clean and contaminated feed or feed ingredients that will last through the 
exposure duration. Once feed has been obtained, researchers must be able to test feed or feed 
ingredients for mycotoxin content and use this information to formulate feeds of known 
mycotoxin concentration. Feed formulation becomes even more challenging with combinatorial 
mycotoxin studies as feed contaminated with individual mycotoxins as well as the combination 
must be produced. In ovo exposures can greatly improve the efficiency of combinatorial 
mycotoxin exposure. In our studies, injection solutions containing individual mycotoxins and 
their combination were created by dissolving crystallized mycotoxins of known purity in 10% 
DMSO. This easily allowed us to control the dose and ratio of mycotoxins in exposure solutions.  
4.3 Advantages and limitations of the in ovo model for mycotoxin screening 
As previously discussed, in vivo responses to mycotoxins are difficult to reproduce often 
leading to under- or over-estimation of mycotoxin toxicity. Lack of reproducibility among in 
vivo studies can also increase animal usage as multiple studies attempt to assess mycotoxin 
toxicity across similar endpoints (i.e. growth performance, organ morphology etc.). This thesis 
research demonstrates that in ovo responses to the mycotoxin, DON, are both repeatable and 
reproducible. Across both experiments, in ovo exposure to DON resulted in significant and 
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consistent morphological alteration including decreased embryo survivability, decreased yolk 
utilization (yolk-free body weight), and increased weight and physical changes in the liver and 
spleen. Effects of mycotoxins on morphological traits tend to vary greatly amongst in vivo 
studies and, in general, are considered insensitive markers of in vivo toxicity (Ghareeb et al., 
2012). Beyond morphology, exposure to DON in both experiments resulted in increased hepatic 
granulopoiesis and lipid peroxidation. Repeatability and reproducibility are measures of 
experimental accuracy. Our data, being both repeatable and reproducible, confirms the precision 
of in ovo mycotoxin exposure and indicates that our findings are an accurate representation of in 
ovo DON toxicity. Factors that may have contributed to the precision of our experiments should 
be addressed. Firstly, fertilized eggs for both exposures were supplied by the same flock, thus, 
genetic influence was consistent. Secondly, by removing the embryos from the egg prior to 
hatch, we removed variability associated with rapid growth immediately post-hatch.  
It is important to note that use of the in ovo model does not constrain experimental 
design. Despite the small size of the chicken embryo (which permits minimal space 
requirements), ample tissue can be collected allowing for various types of analyses. For example, 
in both experiments, liver tissue from a single embryo was sufficient for histopathological, 
biochemical (TBARS), and gene expression analysis. Use of the chicken embryo also allowed a 
full systemic dose-response to be studied. In Chapter 2, we were able to determine a dose-
response relationship for DON toxicity in the chicken embryo and understanding the effect of 
dose on toxicity of mycotoxins is crucial for statistical analysis of individual and combined 
mycotoxin toxicity. 
Metabolic differences between the chicken embryo and the adult chicken are one of the 
main limitations for extrapolating results from an in ovo exposure to the whole animal. In both 
studies, Fusarium mycotoxins were administered into the amniotic fluid of fertilized eggs in 
order to mimic a dietary route of exposure. However, contrasting our findings with previous in 
vivo studies suggests that there may be fundamental differences in mycotoxin uptake and 
metabolism that modify responses to mycotoxins. For instance, the gut is a metabolically active 
tissue and, as such, is known to be susceptible to DON toxicity (Pinton and Oswald, 2014). 
Poultry consuming DON-contaminated diets (5 mg DON/kg feed) typically have lower intestinal 
segment weight and altered gut mucosal structures (e.g. reduced villi height; Awad et al., 2006); 
however, we did not see changes in weight, length and density of the small intestine. We did not 
histologically evaluate mucosal structures in the intestine based on a previous pilot study, where 
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chicken embryos exposed late in incubation (ED18) did not exhibit changes in weight or density 
of the small intestine or in the intestinal mucosal structures of the duodenum, jejunum or ileum. 
Although it is possible that histological, biochemical or gene expression changes occurred in the 
intestine with in ovo exposure to DON, based on the present research, it remains unknown 
whether the characteristic gastrointestinal effects of DON exposure would be manifested in the 
chicken embryo. 
The limited role of microbiota within the gastrointestinal tract of the chicken embryo 
could be regarded as either an advantage or limitation of in ovo mycotoxin toxicity testing. The 
sterility of the chicken embryo gastrointestinal tract allows the effect of mycotoxins to be 
discerned independent of microbial metabolism; however, absence of microbiota does not reflect 
the situation in a post-hatch bird. It is understood that the microbial population of the gut can 
affect the mycotoxin toxicity as some common gut microbes are capable of metabolizing 
mycotoxins to detoxified forms. Moreover, microbial detoxification of DON is considered to be 
an important factor in poultry’s resistance to DON (Lun et al. 1988; He et al. 1992). It was 
hypothesized that, in the present thesis research, a lack of microbial detoxification actually 
contributed to the increased sensitivity of the chicken embryo to DON and the combination of 
DON and ZEA. Therefore, without microbial influence, in ovo responses to mycotoxins may 
only conservatively predict the impact of mycotoxin exposure in the post-hatch bird and may, in 
fact, be exaggerated in comparison.  
 Another potentially limiting factor for in ovo mycotoxin research is the use of purified 
mycotoxins as the contaminant source. First, purified mycotoxins can be very expensive and 
certain mycotoxins that are classified as human poisons (e.g. T-2 toxin) may be difficult to 
obtain due to legislated health and safety regulations. Second, and perhaps more importantly, 
mycotoxins are a diverse group of compounds with many different structures that facilitate 
differing solubilities. When conducting an in ovo combinatorial exposure with purified 
mycotoxins, researchers must consider the individual solubilities of the mycotoxins and select a 
non-toxic vehicle in which they can deliver the combination of mycotoxins. Researchers must 
also be aware of the solution volume they are injecting into the egg as >100 μl of an aqueous 
solution injected into the egg environment can cause toxin-independent mortality (based on a 50-
60 g egg; DeWitt et al., 2005). Thus, some mycotoxin mixtures may not be feasibly tested in ovo, 
as differences in solubility (i.e. polar or non-polar) may necessitate separate vehicles for 
individual mycotoxins and, thus, increased injection volume. 
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4.4 Future Directions 
Overall, the late-term chicken embryo appears to be a conservative indicator of in vivo 
responses to Fusarium mycotoxins alone and in combination. An important factor in 
understanding toxicity of any compound is understanding the systemic toxicokinetics of that 
compound. Indeed, previous research studies investigating the toxicokinetics of DON and ZEA 
have greatly improved our understanding of poultry resistance to these toxins. At present, no 
information is available regarding toxicokinetics of DON and ZEA within the chicken embryo. 
This is not surprising, given that neither DON (Valenta and Dänicke, 2005) nor ZEA (Dänicke et 
al., 2002; Sypecka et al., 2004) are maternally deposited in the egg environment and thus, 
chicken embryos are not exposed to these mycotoxins in a production setting. However, this 
information is critical for comparing toxic effects between the chicken embryo and the adult 
chicken. It is currently unknown how DON and ZEA are absorbed, distributed, metabolized and 
eliminated by the embryo or whether effects of these mycotoxins reported in the current thesis 
research are due to the parent compounds or other bioactivated metabolites that may not appear 
in the adult chicken. Although our results demonstrate similar responses to previous in vivo and 
in vitro work, we cannot confirm that DON and ZEA are eliciting toxicity via the same 
compound. Future research should be directed towards understanding the toxicokinetics of 
mycotoxins within the chicken embryo as this information would help determine the accuracy 
with which the chicken in ovo model predicts the in vivo situation.  
As previously discussed, purified mycotoxins are primarily used during in ovo mycotoxin 
exposure. While this allows researchers to evaluate the toxicity of individual mycotoxins and 
controlled ratios of mycotoxin combinations, it does not reflect the naturally-occurring 
mycotoxin matrix. Indeed, naturally-contaminated feed is generally considered more toxic than 
artificially contaminated sources (Eriksen and Petterson, 2004), which is likely due to interaction 
of masked, previously undescribed or co-occurring mycotoxins interacting with known 
mycotoxins (Schatzmayr and Streit, 2013; Dersjant-Li et al., 2003; Trenholm et al., 1994). 
Future research aimed toward isolating a mycotoxin matrix from grain could improve the 
applicability of the in ovo exposures with respect to mycotoxin exposure. Hypothetically, 
isolated mycotoxins extracted from a grain sample could be crystallized, resuspended in an 
appropriate vehicle, retested to determine mycotoxin concentrations and administered to the 
chicken embryo in the same way purified mycotoxins were applied in this thesis research. This 
would result in an in ovo exposure that more closely resembles a practical, dietary exposure. In 
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this way, the in ovo model might also be used as a rapid screening tool for feed where a 
mycotoxin matrix from a grain sample could be evaluated for toxicity using an effects-directed 
approach. 
In an effort to address the growing concern of mycotoxin contamination in feed, 
appreciable research has been directed toward to development of mycotoxin mitigating products. 
In general, these products are aimed at reducing the toxic effects of mycotoxins by binding the 
mycotoxins, blocking mechanisms of action or through detoxification. Mitigation agents can be 
divided into three distinct groups – physical, chemical and biological methods of mitigation. 
Physical methods including quick drying, UV treatment, floating, near-infrared transmittance are 
typically focused on treatment of grains that reduces the amount or availability of mycotoxins 
prior to feeding (Zhu et al., 2016). However, chemical and biological methods are aimed at 
detoxification or compensation during the feeding process (Zhu et al., 2016). Given that the 
chicken embryo demonstrates adverse responses to mycotoxins, there may be potential for 
chemical and biological methods of mitigation to be trialed in ovo. Mitigation products applied 
in tandem or subsequent to mycotoxin injection could allow researchers to preview mitigation 
product efficacy and to use this information to better inform future in vivo trials. Moreover, this 
type of evaluation could enable privately-owned biotechnology companies to improve approval 
processes for new mycotoxin mitigating agents. This function could ultimately add to the 
industrial relevancy of the in ovo model as feeding programs could be adapted to include 
effective, mycotoxin mitigating additives based, in part, on data generated from in ovo research.   
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